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Abstract 
 
Known for over a hundred years, the human fungal pathogen, Cryptococcus 
neoformans causes cryptococcosis, a life threatening disease. Infection is acquired 
through inhalation of spores or dried yeast cells into the lungs from which the fungus 
can potentially transmit to all body parts; however, the brain is the most affected 
organ.  Once in the brain, the yeast C. neoformans causes meningoencephalitis, a fatal 
condition even with optimal treatment. The mechanism by which C. neoformans 
penetrates the normally impermeable blood brain barrier in not understood. Using 
both in vivo and in vitro models, research in the past decade has demonstrated that the 
pathogen may penetrate the blood-brain barrier through either the Trojan horse 
pathway, hiding inside monocytes and or macrophages, or transcellularly through 
adherence to – and uptake by - brain microvascular endothelial cells. In the first part 
of this thesis, we make the first attempts to quantify the rate of binding and 
internalization of cryptococci by brain-microvascular endothelial cells. By combining 
dual colour microscopy and culture techniques, we have shown that adherence and 
internalization of cryptococci by brain microvascular endothelial cells is a rare event 
characterized by a small number of cryptococci. The rate of association (binding and 
uptake) with brain endothelial cells increases with time of incubation at 37oC, 
although neither presence of capsule nor opsonisation enhances this association 
within isogenic strains of C. neoformans. 
 
In the second part of this thesis we provide the first exploration of the association 
between macrophage - Cryptococcus interaction and clinical outcome of HIV-
associated cryptococcal meningitis. The ability of C. neoformans to parasitize 
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monocytes and macrophages has long been known, a phenomenon by which it is 
believed that these phagocytes systemically disseminate the pathogen from lungs to 
the brain. A panel of 47 isolates from cerebral spinal fluid (CSF) of HIV- associated 
cryptococcal meningitis patients was characterized for a number of traits, including 
rate of uptake by macrophages, intracellular proliferation rate in macrophages, 
melanisation and capsule expression. Association between macrophage – isolate 
interaction phenotype and patient clinical parameters were determined using linear 
and logistic regression models.  We show that high rate of cryptococci uptake by 
macrophages is associated with patient fungal burden whilst the intracellular 
proliferation rate is inversely associated with TNF-α levels in the patient CSF. 
Interestingly, the high uptake – high fungal burden isolates were less encapsulated but 
more rapid melanin formers, traits known to modulate phagocytosis and protection 
from host-induced oxidative stress respectively. We therefore hypothesize that highly 
phagocytosed C. neoformans strains disseminate faster to the brain, resulting in high 
fungal burden by proliferating in the brain tissue and CSF. 
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Thesis overview 
 
This thesis is made of five chapters, the conclusion, future perspectives and the 
appendix. Chapter I covers the Introduction in which the author expounds on the 
importance of cryptococcosis and the literature regarding the mechanism (s) by which 
Cryptococcus neoformans infects the human brain. To reach the brain, the inhaled 
cryptococci must overcome the host’s physical and chemical barriers in the lungs and 
the circulatory system. This implies that C. neoformans may never reach the brain if 
encounters a strong and effective immune response in the lungs. Nevertheless, the 
pathogen is also endowed with protective gears (virulence traits) to enable it survive 
the hostile host defence response and take advantage of host phagocytes as vectors for 
its transmission to the brain. It is important to note that contents of this chapter have 
been submitted for publication as a review in the journal of future medicine. 
 
Chapter II details the methods and materials used, which are divided into two 
sections. First section covers methods and materials for the study of C. neoformans 
interaction with brain microvascular endothelial cells (BMEC). The role of the 
capsule, effects opsonisation, IFN-γ, and viability in Cryptococcus – BMEC 
interaction are examined. In the second section, the author details methods used to 
study macrophage – clinical Cryptococcus interaction. Clinical isolates from HIV-
associated cryptococcal meningitis are characterised for the rate of uptake by 
macrophages, intracellular proliferation inside macrophages, melanisation and capsule 
expression. The section further examines a selection of highly and less internalised 
isolates for their growth in low iron conditions and survival in whole blood from 
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healthy donors as well as rate of association with phagocytes in this blood. Linear and 
logistic regression model is used to determine the association the macrophage – 
isolate interaction phenotype with patient clinical parameters. 
 
Chapter III gives the results from the Cryptococcus – BMEC study. Results in this 
chapter show the percentage association and internalisation of cryptococci by both 
murine and human BMEC at different time points. The effects of opsonisation, IFN-ϒ 
induction of BMEC, and viability on the rate of cryptococci – BMEC interaction are 
shown. As a control to verify that cryptococci binding and uptake observed is to non 
other than BMEC, we show that killing the BMEC monolayer using a fixative 
completely abrogates association and internalization of cryptococci by BMEC. These 
results, methods and discussion thereof have been published (Sabiiti, et. al., 2012). 
 
Chapter IV comprises the results of the macrophage – clinical isolates interaction 
study. Rates of uptake and Intracellular proliferation for all isolates are given. The 
linear regression analysis results showing association between rate of cryptococci 
uptake and intracellular proliferation rate (IPR) as well as patient CSF fungal burden, 
Cryptococcal antigen, White cell and lymphocyte counts and also cytokine, TNF-α 
are given. Association between rate of macrophage cryptococci uptake, IPR and 
melanisation as well capsule expression are also given. The results also show the rates 
at which the high and low uptake isolates grow in different iron conditions, survival in 
whole blood and association with blood phagocytes. The chapter ends with a 
summary of all the determined phenotypic (uptake, IPR, melanisation, capsule 
expression) and the known genetic characteristics of the isolates. 
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Chapter V is the discussion of results from Chapters III and IV. First section discusses 
Chapter III results on Cryptococcus – BMEC interaction and concludes that 
cryptococci association and internalization by BMEC is a rare event characterised by 
small number of cryptococci binding to the endothelium and that this association is 
capsule independent. Second section discusses Chapter IV results and points out the 
rate of cryptococci uptake by macrophages as an important factor in C. neoformans’ 
pathogenicity. Rate uptake is most likely crucial in the lungs when cryptococci first 
encounter alveolar macrophages and the outcome of this interaction sets the pace of 
systemic dissemination of which the high uptake strains disseminate faster to the 
brain. 
 
The thesis ends with conclusion and future perspectives. The conclusion highlights 
that brain infection by C. neoformans is a result of successful manouver of the 
pathogen through the host’s pulmonary and haematogenous defence barriers and that 
the fungus uses multiple means of dissemination and crossing the blood brain barrier. 
Based on the current understanding, the author forecasts and points out the areas that 
are likely to form the basis of Cryptococcus and cryptococcosis research in the 
coming years.!
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1.1 Importance of cryptococcosis 
 
Cryptococcosis is a life threatening disease causing a significant global burden of 
disease. The central nervous system form of the disease, cryptococcal 
meningoencephalitis (or meningitis) is the most severe and accounts for most 
mortality arising from cryptococcosis. One million cases of cryptococcal 
meningoencephalitis (CM) are estimated to occur globally per year, with  >60% 
mortality within 3 months of infection. HIV-associated CM accounts for the majority 
of these cases, 80% of which occur in Sub-Saharan Africa (Park et al., 2009). Despite 
increasing access to antiretroviral therapy, the incidence and mortality of cryptococcal 
meningitis remain high, the diagnosis of HIV frequently being coincident with the 
diagnosis of meningitis (Jarvis et al., 2009; Kambugu et al., 2008; Meya et al., 2010). 
Even when optimal treatment with amphotericin B and flucytosine is available, 
mortality is between 15-30% in both low and high-income settings (Lortholary, 2007; 
Saag et al., 2000), and much higher in low-income countries where such antifungal 
regimens are not readily accessible. In addition, the incidence of non-HIV associated 
CM is increasing in the Pacific North-Western America and Far East Asia caused by 
hypervirulent strains of C. gattii and C. neoformans respectively (Byrnes and 
Heitman, 2009; Chau et al., 2010; Zhu et al., 2010). Lastly, cryptococcosis is the third 
leading fungal infection in solid organ transplant patients (Singh et al., 2008; Singh et 
al., 2009) and thus advancements in organ transplant application and wide use of 
immunosuppressives is prospectively expected to account for increased incidence of 
cryptococcosis in the medically developed world (McQuiston and Williamson, 2012; 
Singh et al., 2008; Singh et al., 2009).  
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1.2 Historical overview 
 
The genus Cryptococcus has been known for over 100 years (Springer and 
Chaturvedi, 2010). First isolated from fruit juice in 1894 by an Italian scientist, 
Sanfelice, the fungus Cryptococcus neoformans was later isolated from milk, humans, 
pigeon droppings and roosting places (Knoke and Schwesinger, 1994; Springer and 
Chaturvedi, 2010). The nomenclature of Cryptococcus neoformans evolved through 
the names Saccharomyces neoformans, Blastomyces neoformans, Cryptococcus 
hominis, and Torula histolytica until the 1950s when the current name was settled on 
(Mitchell and Perfect, 1995). C. neoformans is an encapsulated yeast and, based on 
the immunological reaction to the polysaccharide capsule, the yeast was classified 
into four serotypes: A, B, C and D. Serotypes A and D are characterized as C. 
neoformans var. grubii and C. neoformans var. neoformans while serotypes B and C 
were associated with C. neoformans var. gattii (Franzot et al., 1999; Springer and 
Chaturvedi, 2010). Molecular based typing has led to the recognition of C. 
neoformans var. gattii as a distinct species, Cryptococcus gattii (Boekhout et al., 
1997; Kyung J. Kwon-Chung, Teun Boekhout, Jack W. Fell and Mara Diaz, 2002) 
restricting C. neoformans var. neoformans and C. neoformans var. grubii to serotypes 
D and A respectively (Franzot et al., 1998; Ngamskulrungroj et al., 2009; Springer 
and Chaturvedi, 2010).  
 
The varieties are further divided into molecular types VNI, VNII and VNB of C. 
neoformans var. grubii; VNIV of C. neoformans var. neoformans; VNIII (hybrid, 
serotype AD); and VGI, VGII, VGIII and VGIV corresponding to C. gattii  
(Ngamskulrungroj et al., 2009). The serotype A C. neoformans grubii molecular types 
VNI and VNII have a global occurrence  (Litvintseva et al., 2006; Simwami et al., 
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2011) but VNI accounts for majority of infections in both immunocompitent and 
immunocompromised patients (Heitman Joseph, Kozel Thomas R, Kwon-Chung 
Kyung J, Perfect John R, Casadevall Arturo, 2010). The VNB lineage is 
geographically restricted to Southern Africa (Litvintseva et al., 2006). Recent 
population and phylogenetic studies suggest that C. neoformans var grubii VNI 
originated in Africa (Litvintseva et al., 2011; Simwami et al., 2011). This finding 
follows on the previous phylogenetic study, which suggested an African origin of the 
AD hybrid serotype (Litvintseva et al., 2007).  
 
The first account of human cryptococcosis is attributed to two German Scientists, 
Busse and Buschke who, in 1895, described a 31-year-old woman with a lesion on her 
tibia  (Casadevall and Perfect, 1998). Although many clinical cases of cryptococcosis 
were reported in the 1900s, the prevalence remained generally low until 1947 – 1968 
when high numbers of cases were reported from Africa. The increase in cases is 
presumed to have been due to the emergence of AIDS in the Congo River basin in 
that period  (Casadevall and Perfect, 1998; Molez, 1998; Springer and Chaturvedi, 
2010). The global HIV/AIDS epidemic of the 1980s to present has seen a parallel rise 
in cases of human cryptococcosis, mainly due to the immunosuppressive nature of the 
HIV/AIDS disease (Casadevall et al., 1998; Lin et al., 2009; Mitchell and Perfect, 
1995; Severo et al., 2009). Cryptococcal infection can potentially occur in any part of 
the human body, with cases involving organs such as skin, bone, prostate gland, or 
urinary tract, liver, spleen, lymph nodes, lungs and brain being reported (Hernandez, 
1989; Lin et al., 2009; Liu et al., 2009; Severo et al., 2009).  Of all the cryptococcal 
sites of infection, pulmonary and central nervous system (CNS) are the mainly 
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affected sites with most mortality arising from CNS cryptococcosis (Park et al., 
2009).  
1.3 Ecology and epidemiology 
 
 
The genus Cryptococcus is composed largely of free-living environmental fungi, 
which belong to phylum Basdiomycota (Casadevall and Perfect, 1998). Reports have 
consistently associated C. neoformans with ecological niches such as soil, pigeon 
droppings while C. gattii is mostly associated with trees (Casadevall and Perfect, 
1998; Sorrell, 2001; Springer and Chaturvedi, 2010). Historically, C. neoformans var. 
grubii and var. neoformans are known to have a global distribution while C. gattii 
was said to exist in the tropical and sub-tropical regions (Kwon-Chung and Bennett, 
1984a; Kwon-Chung and Bennett, 1984b; Springer and Chaturvedi, 2010). However, 
the recent Vancouver outbreak of C. gattii cryptococcosis and further cases identified 
in the US and Europe confirms the presence of C. gattii in temperate regions (Bovers 
et al., 2008; Byrnes and Heitman, 2009; Datta et al., 2009; Kidd et al., 2004). The two 
species grow well at environmental temperatures (25oC – 30oC) (Schop, 2007); but 
their ability to grow at physiological temperature (37oC) is fundamental to their 
ability to act as human pathogens (Casadevall and Perfect, 1998).  
 
Cryptococcosis occurs in both animals and humans. Apart from rare examples of 
iatrogenic (Lin et al., 2006), zoonotic (Lagrou et al., 2005), and mother-to-child 
transmission (Sirinavin et al., 2004), no categorical animal-to-human or human-to-
human transmission has been documented.  The ability to cause infection in both 
animals and humans shows that the C. neoformans species complex is not an obligate 
human pathogen. The major environmental sources of C. neoformans are either soil 
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contaminated with pigeon guano for C. neoformans var. neoformans and var. grubii 
or trees (mainly eucalyptus) and decaying wood for C. gatti (Abraham et al., 1997; 
Balankura, 1974; Callejas et al., 1998; Chakrabarti et al., 1997; Fortes et al., 2001; 
Khosravi, 1997; Mahmoud, 1999; Montenegro and Paula, 2000; Pfeiffer and Ellis, 
1992; Sethna et al., 1973; Yamamoto et al., 1995). C. neoformans is largely an 
opportunistic pathogen whilst C. gattii is a primary pathogen and is responsible for 
the least amount of cryptococcal infections globally (Mitchell and Perfect, 1995). C. 
neoformans var. grubii accounts for 95% of cryptococcal infections and 99% of HIV-
associated cryptococcosis (Casadevall and Perfect, 1998; Mitchell and Perfect, 1995).  
Apparently cryptococcosis is neither a zoonosis nor contagious disease and therefore 
infection most likely occurs when humans are exposed to the environment infested 
with cryptococcal spores or dried yeast cells (Figure 1).  
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Figure 1: The transmission cycle of cryptococcal spores or desiccated yeast cells 
from environmental sources to the human body 
Environmental niches such as soil contaminated with bird guano or trees are 
important in the infection cycle. Birds, especially pigeons, are a reservoir and could 
have been responsible for the worldwide transmission. The fungus infects various 
animals such as cats, goats and koalas; can survive environmental predators such as 
insects, worms and amoeba and may interact with other microorganisms such as 
bacteria and fungi. Through inhalation, the fungus establishes pulmonary infection 
where it may stay latent or disseminate to organs, particularly the CNS, depending on 
the immune status of the individual (Adapted from Lin and Heitman, 2006).  Whether 
human infection (both pulmonary and brain) is a dead end in the transmission cycle of 
C. neoformans remains unanswered. However, given the fact that the fungus can live 
saprophytically in the environment there is no reason why it should not survive in 
decomposing human matter (blue broken arrow).   
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1.4 Reproduction 
 
The C. neoformans species complex is capable of both asexual and sexual means of 
propagation. In most clinical and environmental isolates, C. neoformans is mostly 
found as yeast, which is the asexual form of the fungus  (Casadevall and Perfect, 
1998; Lin et al., 2005; Lin and Heitman, 2006). Under culture, the yeast population 
will undergo budding with an average doubling time of 5 – 7hrs (Miller et al., 1990)In 
the perfect state (i.e the teleomorphic, bacidiomycetous, Filobasidiella neoformans) 
(Franzot et al., 1999; Staib, 1981; Sukroongreung et al., 1998). C. neoformans and C. 
gattii are able to reproduce sexually resulting in production of basidiospores  
(Casadevall and Perfect, 1998; Lin et al., 2005; Lin and Heitman, 2006). Basidiospore 
production can result from either haploid (monokaryotic) fruiting or diploid 
filamentation. Mating involves fusion of haploid cells of opposite mating types, a and 
α to produce dikaryotic filaments, which eventually lead to the formation of a 
basidium. In the basidium, meiosis occurs generating four chains of readily 
aerosolized basidiospores (Kwon-Chung, 1976a; Kwon-Chung, 1976b; Sia et al., 
2000; Wickes et al., 1996)(Figure 2). 
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Figure 2: Morphological differentiation in C. neoformans 
(A) Pseudohyphal differentiation. (B) Mating of alpha and a yeast cells secrete 
peptide pheromones that trigger cell–cell fusion under nutrient limiting conditions. 
The resulting dikaryon initiates filamentous growth, and the two parental nuclei 
migrate coordinately in the hyphae. A septum forms to separate the cells, and one 
nucleus is transferred to the penultimate hyphal cell via a clamp connection and clamp 
cell and hyphal cell fusion. During this hyphal growth, blastospores (yeast like cells), 
can bud from the hyphae and divide mitotically in the yeast form. Some hyphal cells 
can enlarge and form chlamydospores. At the stage of basidium development, the two 
nuclei fuse and undergo meiosis to produce four meiotic products that form chains of 
basidiospores by mitosis, and budding from the surfaceof the basidium. (C) 
Monokaryotic fruiting. During monokaryotic fruiting, cells of one mating type, e.g. a 
cells become diploid a/a cells, either by endoduplication or by nuclear fusion 
following cell fusion between two a cells. The diploid monokaryotic hyphae forms 
rudimentary clamp connections, but these are not fused to the preceding cell. 
Blastospores and chlamydospores also form during fruiting as in mating. At the stage 
of basidium development, meiosis occurs and haploid basidiospores are produced in 
four chains (Adapted from Lin et al., 2009).  
(A) 
 29 
Cryptococcus can undergo intervarietal (serotype A x serotype D) and interspecies 
(BxD, CxD) matings, but the viability of the basidiospores is reduced and many 
diploid and aneuploid progeny are generated from these matings, indicating that 
genomic divergence impairs meiosis (Lengeler et al., 2000).  
 
1.5 Pathogenenesis and dissemination to the brain 
 
Human infection is believed to occur through inhalation of airborne propagules from 
an environmental source to the lungs. These propagules are either spores 
(basidiospores) resulting from sexual reproduaction or dried yeast cell. A typical 
cryptococcal yeast cell ranges between 4 – 10µm (Okagaki et al., 2010; Rodrigues et 
al., 1999) but can be as small as 3µm and as large as 100µm (titan or giant cells)  
(Okagaki et al., 2010; Zaragoza et al., 2010) Studies have shown that cell and capsule 
size increases during infection (Okagaki et al., 2010; Zaragoza et al., 2008; Zaragoza 
et al., 2010). A polysaccharide capsule linked to the cell wall on the inner side coats 
the yeast cell but can be shade into the medium as a soluble compound (Okagaki et 
al., 2010; Zaragoza et al., 2008; Zaragoza et al., 2010). Associated with the cell wall 
is the enzyme Laccase, which acts on polyphenolic compounds to produce melanin 
(Zhu and Williamson, 2004) (Figure 3). The capsule and melanin are key factors in 
the pathogenicity of C. neoformans. On the other hand spores are much smaller than 
yeast cells with a size range of 1.8 - 2µm diameter (Rodrigues et al., 1999).  
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Figure 3: A diagrammatic representation of C. neoformans cell 
The capsule forms the largest exterior layer of the yeast and appears white shiny when 
viewed microscopically with India ink staining. Inside the capsule is the cell wall, 
which is associated with enzyme laccase (Lac) and melanin (Mel). The 
polysaccharide capsule is both structural (coats the cell) and soluble (shade into 
medium e.g body fluids like blood, CSF etc) whilst melanin is a byproduct of the 
yeast’s laccase enzyme action on polyphenolic compounds such as L-
dihydroxyphenyl alinine (L-DOPA). The capsule and melanin are major virulence 
factors of C. neoformans (See pages 34, 36 & 37). As eukaryotic organism, C. 
neoformans possesses intracellular organelles such as nucleus, endoplasmic 
reticulum, ribosomes, mitochondria and vacuoles. 
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Colonization of the host can result in: 1) no disease - the fungus is cleared by the host 
immune response; 2), asymptomatic infection in which the fungus enters latency and 
may be reactivated when the host becomes immunocompromised; 3) pulmonary 
disease characterized by pulmonary nodules and inflammation of the lungs (Kishi et 
al., 2006; Wu et al., 2009) and 4) disseminated disease, which can potentially occur in 
all systemic organs with the brain being the most preferred destination (Dromer et al., 
1992; Garcia-Hermoso et al., 1999; Goldman et al., 2001a; Lin and Heitman, 2006; 
Lin et al., 2009). Interestingly, Ngamskulrungroj et al. recently demonstrated that, 
unlike C. gattii, C. neoformans prefers the brain to the lung as a site of infection 
(Ngamskulrungroj et al., 2012). Cryptococcal infection of the brain will depend on the 
successful manoeuvre by the fungus through the barriers involved in the early phase 
of infection. 
1.5.1 Host colonization and pulmonary infection 
 
More than 50 basidiomycetous yeast Cryptococcus species live ubiquitously in the 
environment, but only C. neoformans and C. gattii are significant pathogens of 
humans. The infectious cryptococcal propagules are widely spread in the environment 
and, through inhalation, the spores or dried yeast cells gain access into the respiratory 
tract. Colonization and establishment of infection in the lungs is a process involving 
successful transmission of infectious propagules into the lungs as well as a complex 
interplay of pathogen virulence factors and host immune response.  
!
!
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1.5.1.1 Transmission into the alveolar space 
 
Cryptococcal spores and or dried yeast cells are very small in size and can deposit 
deep in the respiratory tract following inhalation (Velagapudi et al., 2009). The 
kinetic action of host cilia and mucus may serve to drive the infectious particles down 
into the alveolar space (Velagapudi et al., 2009). While spores are largely known to 
mediate transmission from environment into the host by pathogenic fungi such as 
Blastomyces dermatitidis, Histoplasma capsulatum, Coccidioides spp., Aspergillus 
fumigatus, and Paracoccidioides brasiliensis (Giles et al., 2009; Levitz et al., 1986), 
the extent to which cryptococcal spores rather than desiccated yeast cells are 
infectious propagules is still debatable. Recent advances in isolating and 
characterising Cryptococcus neoformans spores has opened up opportunities to model 
infection using spores as infectious particles in order to determine their ability to 
infect and cause disease in the host (Botts et al., 2009; Velagapudi et al., 2009). 
Spores of serotype A C. neoformans var. grubii caused 100% lethal infection in a a 
murine inhalation model of infection and in the invertebrate host Galleria mellonella 
(Velagapudi et al., 2009). Both spores and yeast cells could be aerosolized by a 
stream of air, although there were more aerosolized spores than yeast cells (Botts et 
al., 2009; Velagapudi et al., 2009), suggesting a higher chance of spores being 
involved in environmental dispersal and host exposure.  However, spores are more 
susceptible to killing by activated host alveolar macrophages and are thus speculated 
to depend on rapid germination into mature yeast cells in the host in order to establish 
infection (Botts et al., 2009; Velagapudi et al., 2009). Isolation of C. neoformans 
spores from the environment and characterization of wide range of spores from both 
clinical and environmental strains is needed to further substantiate the potency of 
spores as C. neoformans infectious propagules.  
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The lung alveolar space is lined by a tension reducing fluid, surfactant, which 
promotes adherence of cryptococcal cells to lung epithelial cells (Ganendren et al., 
2006). Surfactant protein-D (SP-D) binds to and promotes phagocytosis of both 
encapsulated and acapsular C. neoformans by macrophages (Geunes-Boyer et al., 
2012), an indication that cryptococcal opsonisation with host surfactant is most likely 
one of the first innate factors mediating transition of cryptococci from extracellular to 
intracellular life. Mannoprotein 1 (MP1) and glucoronoxylomannan (GXM) were 
shown to mediate the binding of cryptococcal cells to SP-D (van et al., 2004). 
Interestingly, SP-D-/- mice were partially protected from cryptococcal infection and 
had reduced lung fungal burden  (Geunes-Boyer et al., 2012). The presence of 
alveolar macrophages that scavenge microbes in the respiratory tract (Gordon and 
Read, 2002) is also likely to drive cryptococci into deeper areas of the respiratory 
tract and lung tissue, since each alveolus contains at least one alveolar macrophage 
(Gordon and Read, 2002).  
1.5.1.2  Pulmonary infection, barrier or stopover for disseminated 
cryptococcosis 
 
Once in the alveolar space, cryptococcal yeast cells may survive extracellularly and/or 
transit into lung tissue by either direct internalization by lung epithelial cells or by 
resident alveolar macrophages (Goldman et al., 2001a; Goldman et al., 2000). At this 
stage, depending on the nature of host immune response, pulmonary colonization in 
which cryptococci are either cleared or develop into a localized latent asymptomatic 
infection. Alternatively, pulmonary involvement can serve as a temporary stopover in 
which cryptococci go on to establish symptomatic infection with subsequent 
dissemination to other parts of the body.   
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Alveolar macrophages comprise 95% of the broncho-alveolar cell population, which 
makes them the predominant first line phagocytes in the lungs (Gordon and Read, 
2002). The interaction of cryptococci with alveolar macrophages most likely 
determines establishment and fate of pulmonary infection and subsequent systemic 
dissemination. Increased fungal burden and extrapulmonary dissemination were 
evident in alveolar macrophage-depleted rats (Shao et al., 2005). Absence of activated 
alveolar macrophages in T – NK cell deficient mice (Tg26) resulted in no granuloma 
formation, conditions under which the attenuated C. neoformans glucosylceramide 
mutants (ΔgcS1) become able to proliferate and disseminate to the brain (Kechichian 
et al., 2007). Cryptococcal phagocytosis and antigen presentation by alveolar 
macrophages induces a Th1 response, which in turn augments alveolar macrophages 
to kill intracellular cryptococci. Furthermore, immunocompetent individuals mount a 
strong Th1 inflammatory response, resulting in the formation of granulomas, which 
contain cryptococci and prevent extrapulmonary dissemination (McQuiston and 
Williamson, 2012). Cryptococcus neoformans’ ability to survive and proliferate inside 
macrophages and reside inside protective granulomas might thus explain latent 
cryptococcosis in immunocompetent hosts.  
 
Studies using the rat model of cryptococcosis have shown that rats mount a strong 
immune response, mimicking that of immunocompetent humans. In this model, 
cryptococcal infection is characterized by granuloma formation and pulmonary 
containment of infection (Goldman et al., 2000). This response is reversed by treating 
rats with an immunosuppressive dose of dexamethasone, resulting in the loss of 
granuloma formation and increased lung fungal burden (Goldman et al., 2000). This 
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mirrors the weak immune response and susceptibility to cryptococcal infection in 
immunocompromised patients. For example, CD4+ lymphocyte deficiency in 
HIV/AIDS patients renders them more susceptible to cryptococcal infection and, once 
infected, the likelihood of disseminated cryptococcosis and involvement of the central 
nervous system is high. Localized pulmonary cryptococcosis is seen in HIV/AIDS 
patients with higher CD4 counts (Meyohas et al., 1995), which further confirms the 
notion that the degree of brain involvement depends on the state of the pulmonary 
immune response.  
1.5.2 Survival and dissemination in the host 
 
Host antimicrobial molecules are designed to destroy both extracellular and 
internalised microbes. Cryptococcus neoformans has, however, evolved mechanisms 
to evade host antimicrobial agents and manipulate the immune response in a manner 
that promotes its survival, replication and persistence in the host.  
1.5.2.1!Antiphagocytic!factors!
!
Capsule expression is a major virulence determinant for C. neoformans, involved in 
both phagocytosis resistance and immune modulation. The Cryptococcus 
polysaccharide capsule is antiphagocytic and consequently highly encapsulated 
strains are less phagocytosed by macrophages (Syme et al., 1999; Zaragoza et al., 
2009). Reduced phagocytosis translates into reduced T-cell proliferation (Syme et al., 
1999) and reduced antigen processing and presentation by macrophages, all resulting 
in an interference with the T-cell response (Vecchiarelli et al., 1994). Large sized and 
highly encapsulated cryptococci were found significantly more frequently in the lungs 
than brain in histopathological sections of a heart transplant patient who died of 
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cryptococcal meningitis (Xie et al., 2012), implying that encapsulated cryptococci 
resist phagocytosis, hence reducing their rate of systemic dissemination. Recent 
studies have demonstrated C. neoformans can deploy multiple antiphagocytic 
strategies, some of which are capsule independent and involve expression of 
antiphagocytic protein, App1 (Stano et al., 2009), and GATA family transcription 
factor, Gat201 (Chun et al., 2011). App1 inhibits phagocytosis through binding 
complement receptors, CR2 and CR3 whereas deletion of Gat201 generates 
hypocapsulated crypotococci that are highly phagocytosed (Chun et al., 2011; Garcia-
Rodas and Zaragoza, 2012).  
 
Phagocytosis avoidance may result in complex effects on dissemination. For instance, 
mating type α (MATα) strains of C. neoformans var.grubii are more likely to 
disseminate to the CNS during coinfection with congenic mating type a (MATa)  
strains via the pulmonary route of inoculation (Nielsen et al., 2005). Interestingly, 
MATa and MATα cells form giant cells during pulmonary infection, which are 
resistant to phagocytosis by macrophages (Okagaki et al., 2010; Zaragoza et al., 
2010). However, in coinfection with both mating types, the proportion of giant MATa 
in the lungs was higher than the MATα cells, one reason why they had a reduced 
chance to disseminate to the brain (Nielsen et al., 2005). Okagaki and Nielsen have 
further confirmed the role of these giant (titan) cells in resisting phagocytosis, but 
they note that titan cell size alone is not enough to induce antiphagocytosis (Okagaki 
and Nielsen, 2012). 
 
Despite the elaborate ability of C. neoformans to resist internalization, the host 
overcomes this evasion through antibody (Casadevall et al., 1992; Dromer et al., 
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1987; Eckert and Kozel, 1987; Kozel et al., 1988; Pirofski et al., 1995; Todaro-Luck 
et al., 1989) and complement (Kozel and Pfrommer, 1986; Kozel et al., 1989). 
However, once inside the phagocyte, C. neoformans shows a remarkable ability to 
survive and proliferate inside mature, acidic phagosomes (Alvarez and Casadevall, 
2006; Ma et al., 2006; Ma et al., 2009). Furthermore the fungus is able to escape from 
macrophages through a non-lytic mechanism and spreads from cell-to-cell (Alvarez 
and Casadevall, 2007; Johnston and May, 2010; Ma et al., 2007), an indication that 
cryptococci can potentially disseminate to the brain by hitchhiking inside phagocytes. 
Research into cryptococcal intracellular life has shown that survival in this hostile 
environment stems from orchestrated expression of both protective and nutrient 
acquisition factors.  
1.5.2.2 Intracellular survival factors 
 
Capsule: C. neoformans produces a complex polysaccharide made of two sugars, 
glucuronoxylomannan (GXM) and galactoxylomannan (GalXM). The capsule both 
forms a structural coating around the yeast cell surface and is secreted into the 
medium (Zaragoza et al., 2009). As well as reducing phagocytic uptake, capsule 
expression protects the fungus from oxidative stress when inside the host cell 
(Naslund et al., 1995; Zaragoza et al., 2008). Capsular material accumulates in the 
phagolysosome and renders it leaky (Lee et al., 1995; Tucker and Casadevall, 2002), a 
process that may allow cryptococci to release factors to inactivate intracellular 
antimicrobial elements or allow for inflow of nutrients, as well as diluting lysosomal 
contents (Garcia-Rodas and Zaragoza, 2012).  
Melanin: Further protection to the fungus is afforded by production of melanin. 
Melanin is a negatively charged hydrophobic pigment of high molecular weight 
 38 
produced by the oxidative polymerization of phenolic compounds (Casadevall et al., 
2000). Melanin production is catalysed by the copper-dependent enzyme laccase, 
produced by C. neoformans when growing on substrates containing polyphenolic or 
polyaminobenzene compounds (Williamson, 1997). Melanin has antioxidant 
properties and protects C. neoformans from oxidative killing by phagocytes. 
Melanised cells have been shown to be resistant to killing both by oxidants (Emery et 
al., 1994) and by antifungal drugs such as amphotericin B and caspofungin (van Duin 
et al., 2002), although recent in vitro susceptibility study shows that C. neoformans is 
generally not susceptible to caspofungin (Messer et al., 2009), implying that the 
observed antifungal resistance may not be melanin dependent but most likely due to 
low potency of the drug. High melanin production has been associated with 
chromosome copy number, in that C. neoformans strains with chromosome 13 
monosomy produced more melanin and were more virulent than their non-melanised 
chromosome 13 disomic counterparts in a murine model of cryptococcosis (Hu et al., 
2011). 
Metabolic machinery: As a natural environmental inhabitant, the fungus grows 
optimally under conditions of good oxygen supply. In addition to the ability to grow 
at the host body temperature of 37oC, cryptococci must adapt to growing under 
hypoxic conditions, particularly when in an intracellular environment. For instance, 
sre1Δ mutant strains, which are impaired in sterol biosynthesis, were unable to grow 
under low oxygen conditions and caused no disease in mouse model of 
cryptococcosis (Chang et al., 2007). A steady supply of energy is crucial for 
cryptococcal intracellular survival and thus glucose utilization mutants (lacking 
pyruvate kinase and or hexokinase I and II) are less virulent in a murine inhalation 
model of cryptococcosis and show decreased persistence in rabbit cerebral spinal fluid 
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(Price et al., 2011). On the other hand, genes involved in peroxosomal lipid 
metabolism were upregulated in macrophage internalized cryptococci and cryptococci 
from mice in the pulmonary phase of infection (Fan et al., 2005; Hu et al., 2008). A 
recent characterization of C. neoformans mitochondrial and peroxisomal β-oxidation 
mutants has shown that such mutants are unable to grow on fatty acids and have 
attenuated virulence in mice (Kretschmer et al., 2012), indicating that, like glucose, 
the metabolism of lipids is essential to C. neoformans survival and dissemination in 
the host.  
1.5.2.3 Nutrient acquisition 
 
Nutrient supply is crucial for both intracellular and extracellular cryptococci in the 
host. Biosynthesis of major virulence factors, melanin and capsule by Cryptococcus 
species require mineral ions such as copper and iron. These minerals are equally 
important to the host physiology, implying that the pathogen competes with the host 
for the precious nutrients. An ability to acquire these minerals under conditions of 
limited availability is essential for cryptococcal survival and pathogenicity. Copper is 
a cofactor for the cryptococcal enzyme laccase, responsible for melanin synthesis 
(Williamson, 1994), and is also involved in capsule biosynthesis through the copper 
transporter-encoding gene, CTR2 (Chun and Madhani, 2010). Acquisition of Cu by C. 
neoformans is believed to be through the copper sensing/transport (CFU1/CTR4) 
system, which, when genetically disrupted, reduces viability and virulence factor 
expression by the fungus. High expression of the copper transporter protein Ctr4 was 
observed in both macrophage-internalized and brain isolated cryptococci, implying 
that copper acquisition is essential for C. neoformans intracellular survival and 
dissemination to the brain (Waterman et al., 2007). Denying C. neoformans access to 
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copper by the copper chelator microplusin reduces growth and completely inhibits 
melanisation in vitro (Silva et al., 2011).  
 
In addition to copper, iron is an essential micronutrient required by many microbial 
organisms. However, high affinity molecules such as haemoglobin, transferrin and 
ferritin tightly bind iron and make availability of free iron very low in the human host 
(Schaible and Kaufmann, 2004). For example circulating transferrin binds ferric 
(Fe3+) iron with a stability constant of 10-20M (Philpott, 2006). To acquire this iron, C. 
neoformans deploys multiple strategies including the high affinity iron transporters 
Cft1 (permease) / Cfo1 (ferroxidase), the siderophore transporter Sit1 and low affinity 
uptake (heme utilization) systems (Jung et al., 2009). The high affinity uptake system 
can acquire ferric iron from transferrin and is able to reduce ferrous (Fe2+) iron to the 
preferred Fe3+ for uptake using the metalloreductase (Fre) system (Jung and Kronstad, 
2008; Jung et al., 2009). Although C. neoformans cannot produce siderophores, it has 
the ability to use sidephores expressed by other microbes in its vicinity, an indication 
that coinfection may exacerbate cryptococcosis by making more iron available to the 
fungus (Jung et al., 2009). The high affinity iron permease cft1 mutants were unable 
to use transferrin as an iron source and showed less virulence and limited 
dissemination in the brains of infected mice (Jung et al., 2009). Additionally, it has 
been shown that C. neoformans can utilize heme as an iron source, (Jung and 
Kronstad, 2008), although the mechanism by which heme iron is accessed is still not 
clear. 
 
Intracellular C. neoformans can also acquire and or recycle nutrients using its own or 
the host’s autophagy system. C. neoformans autophagy genes ATG3 and ATG9 are 
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upregulated within 2hr and 24hr of intracellular life in J774 macrophages respectively 
and autophagy mutants are easily killed by macrophages and cause no disease in 
mouse model of infection (Reviewed in (McQuiston and Williamson, 2012)).  
Equally, C. neoformans can exploit host autophagy mediators to maintain its 
intracellular survival. Using RNA interference (RNAi), Qin et al have demonstrated 
that depletion of macrophage autophagy (Atg) proteins significantly reduces 
intracellular proliferation as well as escape from macrophages (Qin et al., 2011). 
However, a recent study suggests that macrophage autophagy is a complex process, 
which can promote or restrict pathogen growth as well as modulate the immune 
response depending on the host cell type (Nicola et al., 2012).  
1.5.2.4 Immune modulation 
 
The host immune response is a key determinant of cryptococcal pathogenesis. A 
strong Th1 response results in clearance or containment of pulmonary cryptococcal 
infection, but during early stage infection the fungus is thought to polarize the 
immune response towards Th2 to promote its survival and dissemination (Zhang et 
al., 2009). Cryptococcal Urease1 promotes accumulation of immature dendritic cells 
and biases immunity towards Th2 in the lungs, resulting in increased extrapulmonary 
dissemination of the fungus (Osterholzer et al., 2009). Through capsule expression, 
intracellular cryptococci ensure their survival by inhibiting lethal reactive nitrogen 
species, inducing production of anti-inflammatory cytokines and dampening adaptive 
immune responses through blocking antigen presentation (Vecchiarelli and Monari, 
2012). Furthermore, the capsule inhibits IL-6 production by peripheral monuclear 
cells, a process thought to subvert the protective immune response against C. 
neoformans (Siddiqui et al., 2006). On the other hand, a recent study has shown that 
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the C. neoformans prostaglandin E (PGE) inhibits the production of IL-17 by 
differentiating Th17 cells (Valdez et al., 2012). The C. neoformans enzyme laccase is 
responsible for PGE production and consequently laccase mutant (Δlac1) strains were 
less virulent in a murine of infection (Pukkila-Worley and Alspaugh, 2004; Salas et 
al., 1996; Valdez et al., 2012).  
1.5.2.5 Host Cell disruption and barrier penetration 
)
C. neoformans produces degradative enzymes such as phospholipase, proteinase and 
urease and increasing evidence shows that these enzymes act to degrade membranes, 
which subsequently compromises host intracellular and intercellular integrity and  
paves the way for dissemination of the fungus to the brain.. 
 
Phospholipase: Phospholipases are a heterogeneous group of enzymes that are able to 
hydrolyse one or more ester linkages in glycerophospholipids. The Cryptococcus 
neoformans phospholipase enzyme demonstrates phospholipase B (PLB), 
lysophospholipase hydrolase and lysophospholipase transacetylase activities (Wright 
et al., 2004). The action of phospholipases can result in the destabilization of 
membranes, cell lysis, and release of lipid second messengers, promoting interstitial 
lung infection and the dissemination of cryptococci in lymph and blood (Ghannoum, 
2000; Santangelo et al., 2004). Phospholipase B cleaves dipalmitoyl 
phosphatidylcholine, one of the main components of lung surfactant, enhancing 
adherence to lung epithelial cells and thus assisting fungal spread (Ganendren et al., 
2006; Santangelo et al., 2004; Steenbergen and Casadevall, 2003). Furthermore PLB 
enhances both cryptococcal phagocytosis by macrophages and intracellular survival 
(Noverr et al., 2003; Wright et al., 2007). Through Phospholipase B1 action, 
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cryptococci take up macrophage arachidonic acid, which is subsequently used to 
generate eicosanoids (Noverr et al., 2003; Wright et al., 2007). The generated 
eicosanoids can be used to suppress the host immune response and hence promote 
intracellular survival and dissemination of the fungus (Djordjevic, 2010; Noverr et al., 
2003; Wright et al., 2007). Interestingly, there is a correlation between phospholipase 
expression and virulence in a dose dependent manner among strains used to infect 
mice (Chen et al., 1997; Ghannoum, 2000), and hence disruption of the PLB1 gene 
leads to reduced virulence in vivo and growth inhibition in a macrophage-like cell line 
(Cox et al., 2001). PLB1 has also been shown to enhance penetration of the blood-
barrier through activation of host cell Rac1 (the small GTP- binding Rho family of 
proteins) and its association with STAT3 (Maruvada et al., 2012).  
Proteinase: Possession of proteinase by both environmental and clinical isolates has 
been demonstrated to confer the ability to degrade host proteins including collagen, 
elastin, fibrinogen, immunoglobulins and complement factors (Chen et al., 1996). It 
was further proposed that these proteinases, together with phospholipases, enable 
replication of C. neoformans inside the host macrophages by damaging phagosomal 
membranes and thus escaping killing by phagocytic enzymes (Tucker and Casadevall, 
2002). Despite these advances a decade ago, no more work has been done to elucidate 
the mechanism by which proteinases enhance virulence of C. neoformans in the host. 
 
Urease: Urease catalyses the hydrolysis of urea to ammonia and carbamate and is an 
important pathogenesis factor in certain bacteria (Steenbergen and Casadevall, 2003).    
The cryptococcal urease Ure1 is an important virulent factor. Mice infected with 
Ure1Δ mutants live longer than mice infected with the wild type strain H99 (Cox et 
al., 2000). Although urease was not required for growth in the brain, the 
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dissemination patterns to the brain, spleen, and other organs after intravenous 
inoculation differed from the wild type strain, leading to the proposal that Ure1 is 
important for CNS invasion by enhancing yeast sequestration within microcapillary 
beds (such as within the brain) during hematogenous spread, thereby facilitating 
blood-to-brain transmission (Olszewski et al., 2004). This sequestration affected 
cryptococcal adherence and or toxicity to the brain endothelial cells, a view supported 
by Charlier and colleagues’ observation of brain lesions as early as 6hrs after 
intravenous inoculation of C. neoformans (Charlier et al., 2005a). Indeed Shi and 
colleagues, using intravital microscopy for real time imaging of C. neoformans 
transmigration in a murine model, recently demonstrated that cryptococcal Ure1 was 
responsible for increased transmigration sites at the blood-brain barrier (Shi et al., 
2010).  
1.5.3 Dissemination mechanisms: how does the fungus get into 
the brain?  
 
The blood-brain barrier (BBB) ensures that the brain is highly protected, with little 
access by circulating macromolecules and microorganisms. The human BBB is made 
of microvascular endothelial cells supported by astrocytes, pericytes and neuronal feet 
(Correale and Villa, 2009; Weksler et al., 2005). Unlike the peripheral endothelial 
cells, the brain endothelial cells are joined together by tight junctions making the 
BBB a formidable barrier to many pathogens (Weksler et al., 2005).  For C. 
neoformans to infect the brain, cryptococci must penetrate the normally impermeable 
blood-brain barrier (BBB).  The current understanding is that, once in the body, 
cryptococcal yeast cells may use multiple ways to enter the brain (Figure 1: 
Dissemination model of C. neoformans from the environment to the brain). 
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Figure 4: The dissemination model of C. neoformans from the environment to the human brain 
Through inhalation and with the help of mucocilliary movement, spores or dry cryptococci colonize the alveolar space in the lungs (Velagapudi 
et al., 2009) In immunocompetent individuals, activated alveolar macrophages (AMΦ) phagocytose and kill cryptococci and surround 
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cryptococci to form granulomas. Cryptococci in granulomas may stay latent or be reactivated and cause infection once the immune status of an 
individual changes. In immunodeficient individuals, parasitized alveolar macrophages (PMΦ) with intracellular cryptococci act as Trojan horses 
within the lungs, triggering dissemination into systemic circulation (McQuiston and Williamson, 2012). In order to survive in the hostile 
intracellular environment, C. neoformans secretes or enlarges its capsule (Cap), forms melanin (Mel) as an antioxidant against reactive oxygen 
and nitrogen species, prostaglandin E (PGE) to downregulate antimicrobial activity, upregulates nutrient acquisition genes, Ctr4 for Copper and 
Cft1/Cfo1 for Iron and secretes phospholipase (PLB1) which impairs intracellular antimicrobial responses (Emery et al., 1994; Garcia-Rodas and 
Zaragoza, 2012; Jung et al., 2008; Waterman et al., 2007; Wright et al., 2007). Alternatively, cryptococci may resist phagocytosis by growing to 
a very large size (Titan cells), generating a large capsule, expressing antiphagocytic protein (App1) or through the activity of the antiphagocytic 
transcriptional regulator GAT201 (Chun et al., 2011; Okagaki et al., 2010; Okagaki and Nielsen, 2012; Stano et al., 2009; Zaragoza et al., 2009; 
Zaragoza et al., 2010). Extracellular cryptococci may remain localized in the lungs or disseminate transcellularly into the blood circulation.  In 
the systemic circulation, cryptococci associate with monocytes or are carried freely into the brain capillary bed.  In the brain capillary, 
cryptococci may penetrate the blood-brain barrier by either i) riding inside infected monocytes/macrophages (Trojan horse) (Charlier et al., 
2009), ii) transcytosis – binding to and being internalized by brain microvascular endothelial cells (Shi et al., 2010), iii) paracellular traversal 
between endothelial cells, most likely permitted by damaged or weakened tight junctions (Stie et al., 2009).  
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1.5.3.1 Trojan horse dissemination model 
 
The Trojan horse form of dissemination involves parasitized phagocytes such as 
monocytes and/or macrophages smuggling pathogens across the BBB into the brain 
(Charlier et al., 2005b; Charlier et al., 2009; Kim, 2008). The intracellular parasitism 
of monocytes/macrophages has been demonstrated in both in vitro and in vivo models 
(Alvarez and Casadevall, 2006; Feldmesser et al., 2001a; Ma et al., 2006).  A study of 
infected mouse lungs demonstrated an 8hr peak of intracellular cryptococci in 
phagocytes after infection and after day 7 of infection, intracellular cryptococci were 
more abundant than extracellular ones (McQuiston and Williamson, 2012). Following 
phagocytosis, cryptococci survive and proliferate inside macrophages (Alvarez and 
Casadevall, 2006; Ma et al., 2006). Furthermore, live cryptococci can be expelled in a 
novel non-lytic exocytosis (vomocytosis), leaving the host macrophage unharmed 
(Alvarez and Casadevall, 2006; Alvarez and Casadevall, 2007; Johnston and May, 
2010; Ma et al., 2006; Ma et al., 2007). The exocytosed cryptococci then spread to 
other cells (Alvarez and Casadevall, 2006; Alvarez and Casadevall, 2007; Johnston 
and May, 2010; Ma et al., 2006; Ma et al., 2007). This direct cell-to-cell spread 
potentially explains how cryptococci can take advantage of phagocytes to penetrate 
the BBB in a ‘Trojan horse’ manner (Ma et al., 2007). By infecting mice with 
cryptococcal-laden monocytes, Charlier et al. demonstrated the occurrence of the 
Trojan horse traversal of C. neoformans across the BBB in vivo, since mice infected 
with cryptococcal-laden monocytes had high brain fungal burdens compared to mice 
infected with free cryptococci. The originally cryptococcal-laden monocytes 
(labelled) were found in the brain parenchyma indicating that they had penetrated the 
BBB (Charlier et al., 2009). Reduction of disseminated cryptococcosis was observed 
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in alveolar macrophage-depleted immunodeficient mice, which indirectly affirms the 
importance of the Trojan horse model in dissemination of cryptococci (Kechichian et 
al., 2007). 
 
Exploitation of host leukocytes to gain entry into the brain has also been demonstrated 
in other intracellular pathogens such as Listeria monocytogenes, Mycobacterium 
tuberculosis, HIV and the protozoan parasite Toxoplasma gondii (Drevets, 1999; 
Drevets and Leenen, 2000; Drevets et al., 2004; Kanmogne et al., 2007; Lachenmaier 
et al., 2011). T. gondii is a life-long intracellular parasite that infiltrates the BBB by 
hiding in phagocytes and lymphocytes, a process mediated by proinflammatory 
cytokines and involves high expression of endothelial cell adhesion proteins, ICAM 
and VCAM (Lachenmaier et al., 2011; Montoya and Liesenfeld, 2004). The non-
specific lodging of cryptococci in brain capillaries observed by Shi et al, followed by 
transmigration (which is urease dependent) at 6hr might be causal to localized toxicity 
and inflammation (Shi et al., 2010). Inflammation can either result in breakdown of 
intercellular junctions or attract and promote infiltration of inflammatory phagocytes, 
which in the process phagocytose and traffic cryptococcal yeast cells into the brain. 
 
1.5.3.2 Transcellular pathway  
 
This pathway allows pathogens to cross the BBB by transcytosis through the brain 
microvascular endothelial cells (BMEC) by taking advantage of cellular endocytic 
processes (Chang et al., 2011; Charlier et al., 2005a; Jain et al., 2005). A number of 
bacterial pathogens such as Escherichia coli, Group B Streptococcus, Listeria 
monocytogenes, and the fungal pathogen Candida albicans are reported to use the 
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transcytosis pathway (Charlier et al., 2005a; Kim, 2008). Cryptococcal transcellular 
traversal of the BBB has been widely studied using in vitro models of the blood-brain 
barrier, which have demonstrated the ability of C. neoformans to adhere to, be 
internalised by, and traverse brain microvascular endothelial cells (Charlier et al., 
2005a; Vu et al., 2009).  
 
Occurrence of transcytosis across the BBB depends on adherence and internalization 
of cryptococcal yeast cells by BMEC. Chen et al. showed that binding but not 
internalization could occur when cryptococci were incubated with human BMEC at 
37oC and that binding induced cytoskeletal changes (Chen et al., 2003). However, 
using transwell apparatus and electron microscopy, studies by Chang et al and Vu et 
al. have shown that coincubation of brain microvascular endothelial cells with 
encapsulated and acapsular strains of C. neoformans results in both adherence and 
internalization of crypotococci with subsequent penetration of the BBB (Chang et al., 
2004b; Vu et al., 2009). Crossing at the endothelial surface was further demonstrated 
in a murine model of cryptococcosis which showed that cryptococcal yeast cells were 
mostly localized in the brain parenchyma close to brain capillaries and no association 
was observed with the choroid plexus at both early and late stages of infection (Chang 
et al., 2004a; Charlier et al., 2005a). Recent study using real time intravital imaging 
has further elucidated the process of cryptococcal transcytosis across the brain 
endothelium. Six hours after intravenous inoculation cryptococci were seen 
transmigrating across BBB in a manner that involved transcytosis through brain 
endothelial cells (Shi et al., 2010).  
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The nature of interaction between Cryptococcus and brain microvascular endothelial 
cells (BMEC) remains poorly understood. While most bacterial pathogens are 
reported to use receptor-mediated endocytosis to traverse BMEC, no receptor has 
been identified for adherence of C. neoformans to brain endothelial cells (Charlier et 
al., 2005b; Vu et al., 2009). The non-tethered movement and eventual trapping of 
cryptococci in the brain capillaries of similar diameter, described by Shi et al, implies 
that brain endothelium lacks specific surface molecules or receptors to capture 
cryptococci (Shi et al., 2010). However, an independent in vitro study previously 
demonstrated the involvement of glycoprotein CD44 expressed by human brain 
microvascular endothelial cells in enhancing the binding of C. neoformans (Jong et 
al., 2008). Binding!of! CD44 by cryptococcal hyaluronic acid induces downstream 
signaling mediated by protein kinase alpha (PKA-α), which results in cytoskeleton 
reorganisation and phagocytosis of cryptococci by BMECs (Jong et al., 2008). In line 
with CD44 involvement, Sheng-He et al recently demonstrated that CD44 is exposed 
in lipid rafts, through which it interacts with C. neoformans hyaluronic acid, and that 
antibody blocking of CD44 inhibits cryptococcal adherence and uptake by human 
brain endothelial cells (Huang et al., 2011) (Figure 2). The glycoprotein CD44 is a 
widely expressed protein by many cell types (Goodison et al., 1999; Ponta et al., 
2003) and thus Cryptococcus-CD44 interaction may not be specific to the brain 
endothelium alone. However, alternative splicing and post-translational modification 
make the multi-exon CD44 gene functionally diversified in different cell types 
(Goodison et al., 1999; Ponta et al., 2003), and hence investigating the nature of 
BMEC CD44 expression when exposed to cryptococci is needed to determine if the 
interaction is specific to brain endothelium.  Apart from hyaluronic acid, a recent 
study has demonstrated that C. neoformans Phospholipase B1 interacts with lipid 
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mediators in the brain endothelial cell membrane thereby activating GDPrac1 to 
GTPrac1 which then associates with STAT3. The GTPrac1/STAT3 association 
induces cytoskeletal rearrangements resulting in phagocytosis of cryptococci 
(Maruvada et al., 2012)(Figure 2). Other studies have indicated capsule to be 
important in Cryptococcus-brain endothelial cell interaction (Chang et al., 2004a; 
Charlier et al., 2005a; Fries et al., 2001; Guerrero et al., 2006; Ibrahim et al., 1995; 
Jain et al., 2006a). However, these studies demonstrated varying contributions of the 
capsule and/or its absence, leaving the role of capsule in C. neoformans transmission 
across the BBB unclear. By exposing both murine and human BMEC to encapsulated 
C. neoformans serotype A or D and their acapsular mutant derivatives, we have 
recently shown that the binding and uptake of cryptococci by BMEC is capsule 
independent (Sabiiti and May, 2012).  
1.5.3.3 Paracellular pathway  
 
The paracellular pathway involves pathogens traversing the BBB through the 
intercellular spaces (Chang et al., 2004a; Kim, 2008). This mechanism involves the 
pathogen damaging and weakening tight junctions, which join the brain endothelial 
cells together, in order to gain entry. Trypanosoma species are thought to use the 
paracellular pathway (Kim, 2008). Severe damage of the endothelium characterized 
by neuropil edema (neuro-accumulation of fluid) and sequestration of yeast in the 
brain microvessels were observed following cryptococcal penetration of the BBB 
(Charlier et al., 2005b; Olszewski et al., 2004). Furthermore, Chen et al showed that 
cryptococcal binding of the microvascular endothelium induced tight junction 
alteration (Chen et al., 2003). In addition, a recent study has shown that cryptococcal 
mannoproteins bind host plasminogen, which is activated to the effector form, 
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plasmin. Plasmin binds and breaks down extracellular matrix and membrane, thereby 
increasing the chance for paracellular penetration of the blood-brain barrier to occur 
(Stie et al., 2009). Taken together, these data indicate the possibility of cryptococci 
using a paracellular entry by inducing damage or exploiting host mechanisms that 
weaken the brain endothelial cell tight junctions (Figure 2).
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Cryptococcal yeast cells bind to – and are encircled by - microvilli-like protrusions on endothelial cells, resulting in internalization into 
intracellular vacuoles (endosomes) (Chang et al., 2004a). C. neoformans interaction with BMEC induces lipid rafts (GM1) to expose cell 
Figure 5: Cryptococcal interaction of with brain microvascular endothelial cells and subsequent penetration the blood-brain barrier 
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adhesion glycoprotein CD44, which binds cryptococcal hyaluronic acid (Huang et al., 2011; Jong et al., 2001). Hyaluronic acid-coated 
cryptococci bind to CD44 in lipid rafts (GM1) and the interaction induces cytoskeleton rearrangement mediated by protein kinase A-alpha α 
(PKAα) or dual specificity tyrosine phosphorylation-regulated kinase-three (DYRK3) resulting in phagocytosis by – and transcytosis across 
BMEC (Huang et al., 2011; Jong et al., 2001). Alternatively internalisation/transcytosis may occur through GTP-Rac signalling induced by 
secreted C. neoformans Phospholipase B1 (Plb1) (Maruvada et al., 2012). Cryptococcal - Urease (Ure1) can convert urea to Ammonia (Shi et al., 
2010) whereas mannoproteins bind and activate plasminogen to plasmin (Stie et al., 2009). Both Ammonia and Plasmin have damaging effects 
on the extracellular cell matrix and may promote paracellular penetration of the BBB by cryptococci through damaged tight junctions (TJd). 
While it is known that circulating monocytes are attracted to regions of inflammation through which they infiltrate into tissue, factors involved in 
the attraction of cryptococci-laden monocytes to brain endothelium and subsequent penetration of the blood-brain barrier are still unknown. 
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The fact that >95% of cryptococcal meningitis cases are HIV/AIDS patients, often in 
the AIDS state, in which the blood-brain barrier is most likely inflamed and thus more 
permeable, makes the paracellular invasion of the brain quite plausible. During HIV, 
virus-infected monocytes are reported to infiltrate the blood brain barrier in the early 
stages of infection resulting in inflammatory disease and damage to the BBB (Boven 
et al., 2000; Nottet et al., 1997). Moreover, the HIV-1 Tat (trans-activator of viral 
replication) protein has been implicated in damaging the blood-brain barrier by 
inducing apoptosis of brain microvascular endothelial cells with subsequent increased 
permeability (Avraham et al., 2004; Kim et al., 2003). Whether HIV infected 
monocytes or the HIV-1 Tat protein mediate damage of the BBB to promote 
cryptococcal penetration of the BBB remains unknown. Despite the occurrence of 
both diseases among HIV/AIDS patients, there are so far no clinical reports 
associating HIV induced neuroinflammatory disorders (HIV associated encephalitis 
and or dementia) with the occurrence of cryptococcal meningitis, implying that the 
two conditions might occur independently. Interestingly, however, the HIV protein 
gp-41 has been shown to enhance cryptococcal binding to human brain endothelia 
(Jong et al., 2007).  
1.6 Cryptococcal meningoencephalitis 
 
Once in the brain, the fungus causes meningoencephalitis, a severe form of the 
disease, which is uniformly fatal if untreated (Casadevall and Perfect, 1998). Even 
with treatment, mortality can be as high as 30 – 100% in HIV/AIDS cohorts (Bicanic 
and Harrison, 2005; Boulware et al., 2010; Kambugu et al., 2008; Mwaba P. et al. , 
2001; Nussbaum et al., 2010). Patients present with headache, fever, malaise and 
altered mental status and less often with signs such as meningism, papilloedema, 
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cranial nerve palsies, focal neurological deficit and depressed level of consciousness 
(Bicanic and Harrison, 2005). Raised intracranial pressure is the most common 
complication, which results in visual and hearing loss (Bicanic and Harrison, 2005). 
Pathologically, non-HIV CM victims are found with more inflammation of the brain 
tissue and lower numbers of extracellular cryptococci than HIV-associated CM (Lee 
et al., 1996). Postmortems of HIV-associated CM victims showed large number of 
cryptococci in the arachnoid area and this number was associated with raised 
intracranial pressure, suggesting that the accumulation of cryptococci in the arachnoid 
and subsequent obstruction of CSF outflow underlies a raised intracranial pressure 
(Loyse et al., 2010). Cerebral spinal fluid fungal burden has been demonstrated to be 
associated with mortality in HIV-associated cryptococcal meningitis (Bicanic et al., 
2009a).  
 
C. neoformans accounts for 99% of the cryptococcal meningitis cases and is the main 
cause of disease in immunocompromised people, while C. gatti is responsible for the 
remaining  1% of the cases and primarily infects immunocompetent people. Although 
the underlying complications and clinical outcome can be different, the form and 
severity of CM disease does not vary between the two aetiological agents (Mora et al., 
2012; Steele et al., 2010). Treatment guidelines have been designed with 
consideration of the patient’s other underlying conditions such as HIV status or the 
presence of an organ transplant (Perfect et al., 2010). For example intravenous (IV) 
Amphotericin B (AmB) deoxycholate (Ambd) 0.7  - 1.0mg/kg plus flucytosine (100 
mg/ kg) for 4 days followed by 2 weeks of fluconazole 6mg/kg is recommended as 
primary induction and consolidation therapy for HIV infected patients (Perfect et al., 
2010). Despite the different regimens to manage the disease, new antifungal drug 
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development is highly neglected, with the 2002 introduction of Voriconazole being 
the most recent new antifungal to come to market. The current most effective 
antifungal is amphotericin, which is unfortunately toxic and requires sophisticated 
administration procedures that are not easily accessible in resource poor settings 
where cryptococcal meningitis is most prevalent. 
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1.7 Project Aims 
 
Transmission of C. neoforms across the normally impermeable blood-brain barrier 
(BBB) is a pertinent question in cryptococcosis research. Understanding the 
mechanism(s) by which Cryptococcus infects the brain is crucial for developing 
effective therapies to treat the fatal cryptococcal meningoencephalitis. Transcytosis, 
one of the mechanisms put forward to explain the transmigration of the fungus across 
the BBB, occurs through cryptococci adherence and uptake by brain microvascular 
endothelial cells (BMEC) (Chang YC 2004, Vu et al 2009). BMEC are not 
professional phagocytes and we were therefore interested in dissecting how 
cryptococci adhere and traffic across this barrier.  The first part of this thesis thus 
focuses on our attempts to quantify cryptococcal uptake by both murine and human 
brain endothelia and to address a potential role for the fungal capsule in this process.    
 
In the second part of this thesis, we report a systematic study of macrophage-
cryptococci interaction using clinical isolates from cerebral spinal fluid of HIV-
associated crytptococcal meningitis patients and the association between this 
interaction and patient clinical parameters. Extensive previous work by our group and 
others has indicated roles for intracellular survival and growth in driving cryptococcal 
virulence in a hypervirulent outbreak of cryptococcosis (Ma et al 2009).  However, no 
similar study had ever been undertaken for HIV-associated cryptococcosis.   Thus we 
undertook an extensive characterisation of 47 clinical isolates obtained (in 
collaboration with Dr. Tihana Bicanic, St. Georges University of London) in order to 
establish the relative importance of different phenotypic parameters in determining 
clinical progression.   
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CHAPTER II: MATERIALS AND METHODS 
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2.1 BMEC – Cryptococcus interaction study  
2.1.1 Strains and culture 
 
Laboratory C. neoformans strains consisting of two isogenic pairs: 1) Serotype A H99 
and its isogenic acapsular strain cap59 and 2) Serotype D B3501 with its isogenic 
acapsular strain B4131 were used. For phagosome acidification studies, a GFP-
expressing derivative of H99 (Voelz et al., 2010) was used. Strains were propagated 
on YPD agar (1% yeast extract, 1% peptone, 2% dextrose and 1% agar) at 25oC. Prior 
to experimentation, cultures of both strains were grown in YPD broth (1% yeast 
extract, 1% peptone and 2% glucose) at 25oC with rotation at 20rpm overnight. The 
yeast cells were washed with sterile phosphate buffered saline (PBS) and counted 
with a haemocytometer to the required inoculum, 1x106 and 2x106 yeast cells for 
macrophages and endothelial cells respectively. For some assays, yeast cells were 
opsonised with 5µg/ml mouse IgG anti-capsule antibody 18B7 (kind gift from Prof. 
Arturo Casadevall) for 45 – 60 min or stained with 0.5mg/ml FITC (save for the GFP 
expressing H99 strain) for 30min with rotation (Labrolller, Labnet Inc.) at room 
temperature prior to use.  
2.1.2 BMEC tissue culture 
2.1.2.1 Murine brain endothelial cell-line, bEnd3 
 
Immortalized mouse brain derived endothelial (bEnd3) cells were obtained from the 
European Cell Collection Centre, London, and a comparative batch was a kind gift 
from Dr. Mark Gumbleton, Cardiff School of Pharmacy. Cells were grown to 
monolayer confluence in T75 flasks (Greiner, UK) for sub-culturing and or 24 well 
tissue culture plates (Greiner, UK) for binding/uptake assays.  Cells were maintained 
in Dulbecco’s modified Eagle’s medium (DMEM, Sigma Aldrich) supplemented with 
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10% foetal bovine serum (FBS), 1% streptomycin/penicillin and 2mM L-glutamine, 
1% non-essential aminoacids, 1% Sodium pyruvate and 5µM 2-Mercaptoethanol and 
incubated at 37oC with 5%CO2 for 4-6 days when they formed complete monolayer. 
Cells were lifted off plastic using 1X Trypsin EDTA for 5-10min at 37oC and 
passaged 1/10 a number of times until the usable passage or frozen for later use. 
Passages 20 – 35 were used in assays. Freezing was done by suspending cell freezing 
medium (50% DMEM, 40% FBS and 10% DMSO) followed by slowdown freezing at 
-20oC for 1hr, overnight at -80oC and finally long-term storage under liquid Nitrogen. 
2.1.2.2 Human brain endothelial cell-line, hCMEC/D3 
 
HCMEC/D3 cells (a gift from Prof. Jane McKeating, Institute of Biomedical 
Research, University of Birmingham) were grown in endothelial growth medium 2 
(EGM-2, Lonza, UK) in T75 flasks for passaging and or 24 well tissue culture plates 
precoated with Calf Skin collagen (Sigma Alderich, UK). Passages 24 – 29 were used 
in assays. Like bEnd3 cells, hCMEC/D3 cells were detached using Trypsin EDTA, 
passaged 1/10 and or frozen in 90% FBS and 10% DMSO for later use. The tissue 
culture was maintained at 37oC with 5%CO2 for 4-6 days to obtain a fully matured 
cell monolayer.   
2.1.3 Seeding endothelial cells for infection assay 
 
To ensure even growth of cell monolayers, 24-well plates were seeded with 105 
endothelial cells per well and grown at 37oC with 5%CO2 for 4-6 days with media 
change every 2 – 3 days. For microscopic examination, 13mm sterile glass coverslips 
(collagen coated for hCMEC/D3 cells) were inserted into the 24 well plates before 
seeding with endothelial cells, allowing the monolayer to grow on the coverslip, 
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which could then be easily transferred for microscopy.  Prior to infection, tissue 
culture growth medium was replaced with serum free medium and incubated for 1hr 
at 37oC. The cultures were then inoculated with 2x106 yeast cells per well, producing 
an approximate infection ratio of 1:3 (target: effector).  Infections were allowed to 
proceed for either 2hr or 4hr, as described, at 37oC with 5% CO2.  To ensure that the 
infection media did not have negative effect on cryptococcal growth, cryptococci (105 
yeast cells/ml) were directly inoculated into bEnd3 and or hCMEC/D3 infection 
medium and growth recorded over 24hr.   
2.1.4 Cryptococci binding and uptake by BMEC cells  
 
The rate of cryptococcal yeast cell association with BMEC (bEnd3 and hCMEC/D3) 
cells was determined both microscopically and using viable cell (CFU) counts. In the 
former, dual colour fluorescence microscopy (Nikon Eclipse Ti - S, Japan) was used 
to determine associated (adherent and internalized) yeast cells. After infection (1:3 
infection ratio), the non-adherent yeast cells were removed by washing four times 
with sterile PBS and the extracellular adherent yeast cells stained for 10 - 15min with 
20µg/ml calcoflour white at room temperature (adapted from Jong et al., 2001). Since 
mammalian cells are impermeable to calcofluor white, internalized yeast retained the 
green FITC signal while adherent cells stain blue. Nine random fields per coverslip 
were viewed and the internalized and non-internalized yeasts therein counted. 
Association (total number of yeast cells attached or internalized by BMEC) 
internalization were determined and compared to the original inoculum. Since this 
microscopic approach did not distinguish between live and dead cryptococci, we 
exploited colony forming unit (CFU) assays to determine the viability of cryptococci 
that had been internalised by cells of the BBB. After removal of non-adherent 
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cryptococci by extensive washing, endothelial cells were lysed with 200µl sterile 
water for 15min at 37oC to release internalized cryptococci and the lysate plated on 
YPD agar for colony counts (CFU assay). The associated cryptococci were 
determined as the ratio of cryptococcal yeast cells (CFU/ml) to the original inoculum. 
Thus, by comparing data derived both from microscopy (which distinguishes 
internalised from attached cryptococci, but not live from dead cells) and from CFU 
counts (which have the opposite profile) we were able to accurately estimate both 
uptake and survival of cryptococci. The results were recorded as endothelial cell 
associated cryptococci per well, which is equivalent to cryptococci per coverslip for 
microscopy and CFU/ml for colony counts. 
2.1.5 Opsonisation and cryptococci – BMEC interaction 
 
Antibodies to Cryptococcus have been reported to exist in circulation as early as 
childhood (Goldman et al., 2001b). Furthermore, phagocytosis studies using 
macrophages have shown that internalization of cryptococcal yeast cells is enhanced 
by antibody and or complement mediated opsonisation (Bolanos and Mitchell, 1989a; 
Mukherjee et al., 1995a; Vecchiarelli et al., 2002). However, no studies have 
investigated whether adherence and uptake of cryptococci by BMEC requires 
opsonisation. To address this, opsonised and non-oposonized live and heat killed H99 
cryptococci were incubated with BMEC for 2hr and 4hr at 37oC. The rate of 
association and internalization was determined as described in section 2.1.4.  
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2.1.6 Effect of viability on Cryptococcus – BMEC association and 
internalization 
 
We tested whether dead cryptococci adhere and are internalized by BMEC at the 
same rate as live cells. 1ml aliquots of both encapsulated and non-capsulated 
cryptococci were heated at 65oC for 15min prior to infection. Adherent and 
internalized yeasts were determined microscopically. To determine if the yeast culture 
was completely killed, 20µl aliquots were plated on YPD agar and no growth was 
observed. 
2.1.7 Effect of IFN -γ  induction bEnd3 cell – cryptococci 
association 
 
IFN-γ and other inflammatory cytokines such as TNF-α are reported to increase 
expression of cell adhesion molecules by brain-microvascular endothelial cells 
(Dietrich, 2002; Lachenmaier et al., 2011). To investigate whether exposure of bEnd3 
cells to IFN-γ increases the binding and phagocytosis of encapsulated or acapsular 
cryptococci, mature bEnd3 cell monolayers were treated with 100U and 500U of 
mouse IFN-γ in serum free medium 12 prior to the infection assay. Untreated bEnd3 
cells (IFN-γ NIL) were used as negative controls. After 2hr and 4hr of infection, the 
cells were washed four times to remove non-adherent cryptococci and lysed with 
200µl of sterile water for 15min at 37oC. The lysate was diluted to ½ and ¼ and 
plated on YPD agar for colony counts. 
 
 
 
 
 65 
2.1.8 Tracking phagosome acidification in BMEC 
 
To test whether cryptococci that have been internalised into BMEC undergo ‘normal’ 
phagosome maturation, we made use of LysoTracker, (Molecular Probes, UK), an 
acidotropic probe with a fluorophore linked to a weak base, which labels acidic 
organelles in different cell types including endothelial cells (Schroder et al., 2006). 
Mature bEnd3 and hCMEC/D3 cell monolayers were infected with the GFP-labelled 
H99 strain for 2hr and 4hr at 37oC with 5%CO2. After infection, non-adherent yeast 
cells were removed by washing four times with sterile PBS. The cells were then 
treated with 50nM/ml Lysotracker for 30min at 37oC, washed and counter labelled 
with 20µg/ml calcofluor white to stain extracellular adherent yeast.  Cells were fixed 
with PFA 4% in PBS and viewed with fluorescence microscopy to determine 
lysotracker positive yeast cells. Percentage acidification was determined as the 
proportion of endothelial cells with lysotracker positive (red signal) intracellular yeast 
cells to the total endothelial cell population in the viewed fields. 
2.2 Macrophage – clinical Cryptococcus interaction study 
2.2.1 Patients and clinical isolates 
 
Fourty-seven HIV-associated cryptococcal meningitis patients, a fraction of >500 
patients in the four completed clinical trials in Africa and Asia were the source of the 
47 Cryptococcus neoformans isolates we studied. Patients were ART naïve under the 
clinical trials for a combination of antifungal regimens. Baseline patient clinical 
parameters including fungal burden, fungal clearance, mental status, 2 and 10 weeks 
mortality were determined. From patient CSF cultures the isolates were obtained and 
preserved (Dr. T Bicanic and group, St. Georges University of London) (Table 1).  
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Patient 
code
CD4 
count Neuts Lymphs WBC Protein  Glc
CrAG 
(Log2)
Fungal load 
(Log10) Slope
TNF 
(Log10)
IL6 
(Log10)
IFN 
(Log10) OP
Mental 
Status
2 Wk 
M
10 Wk 
M Isolate
20 20 ND ND 2 0.2 4.8 8 5.778151 -0.088 0 1.30792 0 8 0 0 1 CM20
24 97 18 202 220 0.34 3.2 6 4.633469 -0.269 0.83187 2.71451 1.2615 24 0 0 0 CM24
36 14 ND ND 0 1 3.8 2 2.816241 -0.939 1.33886 2.81378 1.95804 ND 0 0 0 CM36
50 8 ND ND 3 0.58 2.4 6 4.153815 -0.586 1.20412 3.13441 1.65456 20 0 0 0 CM50
52 8 ND ND 5 0.94 2.7 11 5.322219 -0.264 1.27531 3.15122 1.67256 31 0 0 0 CM52
64 ND ND ND 1 0.33 2.7 9 6.389166 -0.647 1.00689 2.96881 1.4387 27 0 0 0 CM64
102 4 0 0 0 0.6 1.7 12 6.39794 ND 1.02646 1.69897 0 40 0 1 1 CCTP02
103 56 0 2 2 1.6 0.3 11 5.961421 -0.38 2.05567 2.06752 1.88066 76 0 0 0 CCTP03
110 18 0 15 15 0.86 1.3 9 6.612784 -0.398 1.9614 1.69897 1.78432 37 0 0 1 CCTP10
112 21 0 0 0 0.52 3.3 11 6.518514 -0.364 0 3.96827 0.37778 39 0 0 0 CCTP12
113 37 3 1212 1215 4.1 2.1 12 5.149219 -0.122 ND 2.62598 ND 9 0 0 0 CCTP13
125 19 31 72 103 0.9 1.1 10 6.290035 -0.472 2.09287 ND 1.92801 ND 0 0 ND CCTP25
126 ND 0 0 0 1.2 1.9 11 6.118926 ND 1.0961 4.28071 0.55387 34 1 1 1 CCTP26
129 21 0 0 0 0.44 2.9 9 5.352182 -0.92 0 2.94644 0.71022 7 0 0 0 CCTP29
130 42 0 5 5 0.84 2.3 10 6.525045 -0.421 0.2982 3.81584 0 12 0 0 0 CCTP30
149 74 8 124 132 0.92 1.8 9 2.612784 -0.123 1.34598 4.39002 2.26801 53 1 0 0 CCTP49
152 41 0 25 25 1.06 0.3 13 6.332438 0.029 1.94804 3.72876 2.15834 ND 1 0 1 CTTP52
203 8 0 2 2 0.84 2.4 15 6.40654 -0.428 1.02213 0 1.51196 30 0 0 0 RCT03
206 14 1 13 14 0.6 1.0 12 5.361728 -0.553 1.88278 2.81257 2.19399 35 0 0 0 RCT06
207 12 0 1 1 0.3 2.4 11 5.961421 -0.262 0.58915 0.41996 0.73002 80 0 0 0 RCT07
221 7 0 0 0 0.49 2.2 15 5.76342799 ND 0.69973 0.87967 1.08473 32 1 1 1 RCT21
224 9 0 0 0 0.41 2.3 9 6.273001 -0.393 0.40738 1.54307 0.94263 20 0 0 0 RCT24
CSF Parameters
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233 2 0 0 0 0.48 3.0 5 3.612784 -0.723 0.14617 0.78746 1.66345 10 1 0 1 RCT33
236 9 0 0 0 0.32 3.5 13 6.361728 -0.546 0.72643 0.5172 0.68171 15 0 0 0 RCT36
244 44 0 22 22 1.08 1.9 12 6.283301 -0.502 1.02213 2.11893 1.71844 19 0 0 0 RCT44
250 31 0 36 36 1.45 1.7 14 6.361728 -0.791 1.22573 1.97011 2.10544 38 0 0 0 RCT50
251 40 0 19 19 0.98 1.2 12 6.002166 -0.651 0.49786 2.41774 1.53762 6 1 0 1 RCT51
252 163 0 93 93 3.15 1.6 13 6.332438 -0.391 1.11316 2.15652 1.71844 5 0 0 0 RCT52
254 58 0 13 13 0.71 2.4 12 5.643453 -0.311 0.84335 1.13033 1.33776 10 0 0 0 RCT54
255 2 0 0 0 0.42 2.6 13 6.886491 -0.273 0.52301 1.3969 0.99533 18 0 0 0 RCT55
260 115 0 207 207 1.06 1.2 14 6.447158 -0.785 0.94969 1.81624 1.27734 32 1 1 1 RCT60
401 151 2 344 346 0.91 2.2 9 4.96614173 -0.575 0.90741 3.04302 1.75005 ND 0 1 1 IFN1
402 37 0 449 449 1.02 2.1 11 5.62324929 -0.418 1.27161 3.19192 2.13293 35 0 0 0 IFN2
404 13 0 0 0 0.55 0.7 12 5.80277373 -0.411 0.36922 1.82814 1.23603 26 0 0 0 IFN4
405 48 0 0 0 0.82 2.6 9 4.5797836 -0.42 0.43457 2.28176 0.93399 26 0 0 0 IFN5
406 58 40 100 140 3.08 0.4 11 6.44715803 -0.411 0.49415 3.13502 1.16077 31 0 0 1 IFN6
408 27 8 211 219 2.65 2.0 8 2.54406804 -0.287 0.85914 2.7102 1.63829 36 0 0 0 IFN8
409 86 0 57 57 1.54 2.4 10 5.38916608 -0.661 1.22737 4.0992 1.9429 34 0 0 0 IFN9
410 18 0 0 0 0.4 2.8 10 5.72835378 -0.29 0.85914 2.0404 0 41 0 0 0 IFN10
411 37 0 0 0 1.92 0.1 12 5.81291336 -0.485 1.33122 3.49171 1.93344 53 1 0 1 IFN11
412 99 8 33 41 1.15 2.7 11 6.35218252 -0.349 0.67486 3.93972 1.82223 18 1 1 1 IFN12
415 7 0 2 2 0.6 3.7 12 6.03342376 ND 0 2.33486 0 17 1 1 1 IFN15
416 12 0 0 0 0.66 2.0 13 6.63848926 -0.377 1.1784 2.80957 1.29798 10 0 0 0 IFN16
417 ND 0 132 132 1.93 1.1 12 6.06632593 ND 1.02776 3.74477 2.01047 ND 0 1 1 IFN17
418 25 0 65 65 2.61 1.6 8 4.92427929 -0.549 1.02776 3.86212 1.9429 27 1 0 0 IFN18
419 242 0 56 56 1.96 2.1 8 4.52504481 -0.506 0.54654 2.5737 0.93399 34 0 0 0 IFN19
424 19 0 5 5 0.37 2.2 10 5.8419848 ND 0.36922 2.45676 0 25 0 1 1 IFN24  
Table 1: Patient charateristics from whom the isolates were taken  
Baseline parameters: CD4 count at admission, mental status (0 = normal, 1 = altered), CSF - neutrophils (Neuts, mm3/CSF), lymphocytes 
(Lymphs, mm3/CSF), white blood cell count (WBC, mm3/CSF), protein (g/L), glucose (Glc, g/L), Cryptococcal antigen titre (CrAG), fungal load 
(log CFU of quantitative cryptococcal cultures), pro-inflammatory cytokine (TNF, IFN, IL-6) levels (pg/mL), opening pressure (OP, cmH2O), 
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and slope (rate of fungal clearance during antifungal treatment), 2 and 10 week mortality (0 = live, 1 = died) were determined. Patient – isolates 
CM20 – 64 were obtained from the Thailand study; CCTP02 – 30, RCT03 – 60, IFN1 – 24 were obtained from the South African study. ND = 
Not determined. Dr. Tihana Bicanic, St. Georges University of London, provided the patient data and the isolates. 
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Parameter 
Statistic: Median (range) unless 
indicated 
Baseline CSF fungal load (CFU/ml of 
quantitative cryptococcal culture) 9·15 x 105 (3.5 x 102 – 7.7 x 106)  
CD4 count at admission 23 (2 - 242) 
CSF Cryptococcal antigen (CrAG) titre 2.05 x 103 (4 - 3.28 x 104)  
CSF glucose (mg/dl) 2·2 (0·1 - 4·83)  
CSF lymphocytes 13 (0 - 1212)  
CSF neutrophils 0 (0 - 40)  
CSF opening pressure (cm H2O) 27 (5 - 80)  
CSF protein 0.86 (0.2 – 4.1)  
CSF white cell count 5 (0 - 1215) 
Mental Status 11/47 (23% altered mental status) 
2 week mortality 9/47 (19% mortality) 
10 week mortality 14/47 (29.8% mortality) 
Pro-inflammatory cytokine levels:   
IFN-γ 1.48 (0 – 2.28) 
TNF-α 0.93 (0 – 2.09) 
IL-6 2.59 (0 – 4.39) 
SLOPE (rate of fungal clearance) -0.42 (-0·94 – 0.03) 
 
Table 2: Summary of the patient clinical parameters  
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2.2.1.1 Isolate characteristics 
 
All isolates were isolated from CSF of HIV-associated cryptococcal meningitis and 
span a 7-year period of collection from 2002 - 2009. 6/47 (12.8%) came from the 
Thailand clinical study (Brouwer et al., 2004) while the rest (87.2%) are from the 
three clinical studies in South Africa (Bicanic et al., 2007; Bicanic et al., 2008; 
Bicanic et al., 2009b) Out of the 47 isolates, 30/47 (63.8%), 30/47 (63.8%) and 31/47 
(65.9%) had their mating type, MLST and molecular type (VN) known. The 30 
isolates were 100% α mating type but were very diverse in terms of MLST although 
the all the six Thailand isolates were MLST 6. All the 31 known molecular types were 
C. neoformans var. grubii represented by VNI (n = 28), VNII (n = 2) and VNB (n = 
1). VNI makes 90.3% of the known molecular types in this set of isolates (Table 3). 
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Isolate Site*of*
isolation
Year*of*
isolation
Region*of*
origin
Mating*
type
MLST VN*type
CM20 CSF 2002 Thailand α 6 VNI
CM24 CSF 2002 Thailand α 6 VNI
CM36 CSF 2002 Thailand α 6 VNI
CM50 CSF 2002 Thailand α 6 VNI
CM52 CSF 2002 Thailand α 6 VNI
CM64 CSF 2002 Thailand α 6 VNI
CCTP2 CSF 2005 South:Africa α 37 VNI
CCTP3 CSF 2005 South:Africa α 5 VNI
CCTP10 CSF 2005 South:Africa α 57 VNI
CCTP12 CSF 2005 South:Africa α 58 VNI
CCTP13 CSF 2005 South:Africa α 5 VNI
CCTP25 CSF 2005 South:Africa α 51 VNI
CCTP26 CSF 2005 South:Africa α 51 VNI
CCTP29 CSF 2005 South:Africa α 51 VNI
CCTP30 CSF 2005 South:Africa α 5 VNI
CCTP49 CSF 2005 South:Africa α 66 VNII
CCTP52 CSF 2005 South:Africa α 52 VNII
RCT3 CSF 2005/2006 South:Africa α 51 VNI
RCT6 CSF 2005/2006 South:Africa α 6 VNI
RCT7 CSF 2005/2006 South:Africa α 51 VNI
RCT21 CSF 2005/2006 South:Africa α 56 VNB
RCT24 CSF 2005/2006 South:Africa α 1 VNI
RCT33 CSF 2005/2006 South:Africa α 51 VNI
RCT36 CSF 2005/2006 South:Africa ND Diploid VNI
RCT44 CSF 2005/2006 South:Africa α 54 VNI
RCT50 CSF 2005/2006 South:Africa α 74 VNI
RCT51 CSF 2005/2006 South:Africa α 23 VNI
RCT52 CSF 2005/2006 South:Africa α 32 VNI
RCT54 CSF 2005/2006 South:Africa α 75 VNI
RCT55 CSF 2005/2006 South:Africa α 51 VNI
RCT60 CSF 2005/2006 South:Africa α 76 VNI
IFN1 CSF 2007/2009 South:Africa ND ND ND
IFN2 CSF 2007/2009 South:Africa ND ND ND
IFN4 CSF 2007/2009 South:Africa ND ND ND
IFN5 CSF 2007/2009 South:Africa ND ND ND
IFN6 CSF 2007/2009 South:Africa ND ND ND
IFN8 CSF 2007/2009 South:Africa ND ND ND
IFN9 CSF 2007/2009 South:Africa ND ND ND
IFN10 CSF 2007/2009 South:Africa ND ND ND
IFN11 CSF 2007/2009 South:Africa ND ND ND
IFN12 CSF 2007/2009 South:Africa ND ND ND
IFN15 CSF 2007/2009 South:Africa ND ND ND
IFN16 CSF 2007/2009 South:Africa ND ND ND
IFN17 CSF 2007/2009 South:Africa ND ND ND
IFN18 CSF 2007/2009 South:Africa ND ND ND
IFN19 CSF 2007/2009 South:Africa ND ND ND
IFN24 CSF 2007/2009 South:Africa ND ND ND
 
Table 3: The characteristics of clinical isolates used in the study  
Fourty-seven isolates, 6 from Thailand and 41 from South Africa were studied. All 
isolates were derived from CSF of HIV-associated CM. Molecular, mating and 
sequence types were known for 31, 30 and 30 isolates respectively. One isolate was 
diploid. VNI makes 90.3 % of the known molecular types. ND = Not done. 
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Like the BMEC – Cryptococcus interaction assays, isolates were propagated in YPD 
medium prior macrophage infection or phenotypic characterization. 
2.2.2 Macrophage tissue culture 
2.2.2.1 Murine macrophage-like cell-line, J774 
 
Prior to use, 105 J774 macrophages were grown in 24 well tissue culture plates 
(Greiner) containing DMEM supplemented with 10% FBS, 1mM L-Glutamine and 
1% Penicillin/Streptomycin for 24hr at 37oC with 5% CO2. Macrophage batches used 
were kept within the range of three passages to limit passage-to-passage variations. 
From frozen, J774 macrophages were propagated at 3/12 until passage 7 before they 
were used for assay.  
2.2.2.2 Primary human macrophages 
 
Primary human macrophages were obtained through differentiation of monocytes 
from buffy coat of health donors (Birmingham Blood Bank). Peripheral blood 
monoclear cells (PBMCs) were isolated by Ficoll gradient centrifugation. Briefly, 
buffy coat was dissolved 1:1 in sterile PBS. 25ml of the mixture was then carefully 
pipetted onto 20ml of Ficoll-Paque (GE Healthcare Life Sciences) and centrifuged for 
40min, 3200g at 20oC. Centrifugation divided the mixture into 4 layers from which 
the upper middle white layer containing peripheral blood mononuclear cells (PBMC) 
was drawn out into a new tube. The PBMC population was washed with sterile PBS 
x5 – 7 times with spinning, 1057g at 25oC to remove platelets. Monocytes were 
isolated from the PBMC population through adherence to plastic following overnight 
culture in Tissue culture flasks (T75 Greiner) in RPMI 1640 medium with L-
Glutamine (GIBCO) supplemented by either 10% AB male human serum (First Link, 
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UK) or 10% FBS (Sigma) plus 1% Penicillin/Streptomycin in presence or absence of 
1000U/ml Granulocyte macrophage colony stimulating factor (GM-CSF). Monocytes 
were counted and propagated in 24 well Tissue culture plates with 10% FBS, 1% 
Penicillin/Streptomycin – RPMI 1640 medium for 14 days to differentiate into 
macrophages before use.  Medium was changed every 3 days. 
2.2.3 Phagocytosis and Intracellular proliferation assay 
 
Clinical Cryptococcus isolates were tested for the rate at which they were 
phagocytosed by – and proliferated inside - murine J774 macrophages. Prior to 
infection, J774 macrophages were activated with 15µg/ml Phorbol myristate acetate 
(PMA) for 30-40min in serum free medium. Macrophages were infected with 
opsonized cryptococci at 1:10 ratio and incubated for 2hr (time point zero), 18hr (time 
point one), 24hr (time point 2) and 48hr (time point three) at 37oC with 5%CO2. At 
2hrs, the infection medium was aspirated off and macrophages extensively washed (4-
5 times) with sterile PBS to remove extracellular adherent cryptococci. Part of the 
culture was lysed with 200µl of sterile water for 20min at 37oC to release intracellular 
cryptococci, which were counted using a haemocytometer. At time points one, two 
and three cultures were gently washed x2 to rinse off extracellular cryptococci, lysed 
and counted as at time point zero. Rate of phagocytosis (uptake) was determined as 
the number of cryptococci engulfed by macrophages by 2hr of incubation whereas 
intracellular proliferation rate (IPR) was determined as the ratio of number of 
intracellular cryptococci at 18hr to the number of intracellular cryptococci at 2hr. 
 
Eleven high (n=5) and low (n=6) uptake isolates in murine J774 macrophages were 
selected and tested in primary human macrophages. Prior to infection, the human 
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monocyte-derived macrophages were stimulated with 1000U/ml rhIFN-γ 
(Immunotools, German) and 10µg/ml LPS (Sigma Aldrich) 24hr before the assay.  
Rate of cryptococci uptake and IPR were determined as with J774 macrophages.  
2.2.4 Non-opsonisation and cryptococci – macrophage interaction 
 
To evaluate opsonin influence on cryptococci uptake and IPR in macrophages, a no 
opsonisation assay was set. Cryptococci were harvested from 24hr YPD cultures, 
washed with PBS and counted to the required inoculum, 1x106 yeast cells and directly 
added to macrophages without opsonisation. Rate of uptake and IPR were determined 
as in section 2.2.3.  
2.3 Determination of melaninisation and capsule expression 
2.3.1 Melanisation 
 
Through secretion of the phenoloxidase enzyme, C. neoformans can use host 
catecholamines to produce melanin (Polacheck et al., 1982; Polacheck et al., 1990). 
Melanin is resistant to reactive oxygen and nitrogen species generated by host 
phagocytes. The rate of melanization of each isolate was determined by plating 5µl of 
the fresh yeast culture on L-2, 3-dihydroxphenylalanine (L-DOPA) agar (0.7% L-
DOPA, 0.9% Vitamin B1, 3.4% Glycine, 4.2% MgSO4, 9.5% Glucose, 12.1% 
KH2PO4 and 69.3% Agar).  Plates were incubated at 37oC to determine melanin 
formation (colony browning) and scored daily for 15 day. The samples were also 
tested for melanisation at 25oC and compared with rates at 37oC. An arbitrary scale of 
0 – 5 (0 = No browning; 5= Maximum browning) was used to determine the rate of 
melanization (Appendix 1: Melanisation scores).  Melanization rate (MR) was thus 
calculated as the ratio of maximum browning to the number of days taken to attain 
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maximum browning. For clinical isolates, the rate of melanin was tested for a 
statistical association with rate of cryptococcal uptake by – and intracellular 
proliferation in - macrophages. 
2.3.2 Capsule induction 
 
To promote capsule induction in vitro, C. neoformans isolates were inoculated into 
SD broth and grown overnight at 37°C with shaking.  The following day 20 µl of 
culture was inoculated into 5 ml capsule inducing media (DMEM with 1% NCTC 109 
medium, 10% heat-inactivated foetal bovine serum, Sigma Aldrich) and incubated at 
37°C with 10% CO2 for 48 hr.  Cells were subsequently harvested by centrifugation at 
2000 rpm for 5 min and observed by counter-staining with India Ink, using a 40X 
brightfield objective, and measured using ImageJ v1·440 (National Institutes of 
Health, USA) (work done by Dr. Emma Robertson, St. Georges University of 
London). The rate of capsule expression was also analyzed for correlation with rate of 
uptake, IPR and patient fungal burden. 
2.3.3 Iron utilization 
 
Iron is important in virulence of C. neoformans because it influences the biosynthesis 
of major virulence factors, melanin and capsule (Jung and Kronstad, 2008).  A set of 
selected high and low uptake clinical isolates were investigated for their ability to use 
different Iron sources (Work done as part of research visit to Prof. James Kronstad, 
University of British Columbia, Vancouver).   
!
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2.3.3.1 Iron media preparation  
 
Low Iron water was prepared first by passing double distilled water (2L) through 5g 
Chelex 100 resin (BioLabs) in a flex column (Fisher Scientific) to remove all divalent 
metallic ions.  To make 1L of Low iron medium (Lim), 5g Glucose, 5g L-Asparagine, 
4.78g HEPES, 0.4g KH2PO4, 1.85g NaHCO3 were added to low iron water and pH 
adjusted to 7.2 before adding 400µl 1M MgSO4, 340µl 1M CaCl2 and 400µl of 
4mg/ml Thiamine and 1ml 1000X salt solution (5mg CuSO4.5H2O, 2g ZnSO4.7H20, 
10mg MnCl3.4H2O, 0.460g Sodium Molybdate, 5.7mg Boric acid per in 1L of Low 
iron water). The mixture was filter sterilized or autoclaved before use. Transferrin and 
Hemin media were prepared by adding 1mg human Holo-transferrin (Sigma Aldrich) 
and 100mM Porcine Hemin (Sigma Aldrich) respectively to 100ml of Low iron 
medium. 
2.3.3.2 Iron utilization assay 
 
Iron utilization ability was measured as a function of rate of growth in different Low 
iron media. Prior to the growth curve determination, cryptococci were harvested at 
4500g from overnight YPD culture, washed x3 with sterile low iron water and grown 
in Lim for 3 days to reduce their iron reserves. Following iron starvation, yeast cells 
were harvested and washed x2 in low iron water, counted by a haemocytometer to the 
inoculum size of 105 cells /ml. Four media: Lim, Lim-Transferrin, Lim-Hemin and 
YPD as a control were inoculated and incubated at 37oC with shaking at 200rpm for 7 
days. After every 24hr, 100µl aliquots were taken, 10-fold diluted to 1/105 and plated 
on YPD agar for colony counts. Growth curve per isolate per medium was plotted 
exponentially as the number of CFUs versus time in days and the slope of each curve 
was calculated and used to determine rate of growth.     
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 2.4 Whole blood characterization of high uptake and low 
uptake isolates 
2.4.1 Whole blood survival assay 
 
Whole blood from six (4 male and 2 female) healthy donors was obtained at different 
days and infected with a selection of high uptake, n = 5 isolates; and low uptake, n = 6 
isolates.  Each milliliter of blood was inoculated with 104 cryptococci per isolate and 
incubated for 8hr at 37oC with minimal rotation (Labroller). 100µl aliquots were taken 
at different time points (10min, 30min, 1-, 2-, 3-, 4-, and 8 hr) and plated in 4 
replicates of 25µl on YPD agar. Colony forming units were counted after 48hr of 
incubation at 25oC and recorded as CFU/ml. To confirm the viable cryptococci 
present in the initial inoculum, an aliquot was suspended in sterile phosphate buffered 
saline (PBS) and plated on YPD agar for colony counts. 
2.4.2 Blood phagocyte-cryptococci association assay 
 
Cryptococci association with circulating neutrophils and monocytes/macrophages in 
whole blood was measured by flow cytometry (FACSCaliber and CellQuestPro 
software, BD Biosciences). Prior to inoculation, cryptococci were stained with 
0.5mg/ml FITC (Invitrogen) for 30min at room temperature with rotation (Labroller), 
washed and counted with a haemocytometer to the required inoculum, 104 cryptococci 
per 1ml of blood. Two replicates of culture per isolate were made and incubated at 
37oC with 5% CO2 for two time points (30min and 60min). After incubation, 
erythrocytes were eliminated by lysis in 5ml of lysis buffer (12mM Na hydrogen 
carbonate, 0.25mM tetrasodium EDTA and 15mM ammonium chloride) followed by 
5min spin at 1057g and the pellet resuspended in 0.5 ml sterile PBS for flow 
cytometry. Forward and side scatter was used to distinguish neutrophil and 
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macrophage/monocyte populations. By FITC fluorescence, cryptococci associated 
phagocyte cells were distinguished from free phagocytes. 
2.5 Genetic characterization of high uptake and low uptake 
isolates 
 
We hypothesized that there is differential expression of genes between high uptake 
and low uptake isolates than influence the rate of phagocytosis. Isolate RNA was 
extracted before the phagocytosis assay in order to detect which genes were expressed 
before cryptococci interact with macrophages (work done as part of the collaborative 
research visit to Prof. James Kronstad, Michael Smith Laboratories, University of 
British Columbia, Vancouver, Canada). 
2.5.1 RNA extraction  
 
Total RNA was extracted from a set of high uptake (n=4) and low uptake isolates 
(n=4) and the H99 C. neoformans serotype A strain as a reference.  Prior to RNA 
extraction, strains were grown in a pre-phagocytosis medium (YPD broth) for 24hr. 
RNA was then extracted using the RNAeasy mini kit (Qiagen) according to 
manufacturer’s guidelines. The quality and quantity of RNA were assessed using 
Nanodrop, agarose gel electrophoresis and Bioanalyzer (Appendix 2: Bioanlysis 
results of RNA extracts).   
2.5.2 Sequencing and gene expression analysis 
 
RNA sequencing was done using the Illumina RNAseq technology by Data2Bio, 
Iowa, USA. Eight pairwise comparisons were performed between clinical isolates and 
reference strain, H99. This was followed by sixteen binary sequence alignments 
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between the high and low uptake isolates to determine the differentially expressed 
genes. Geneontology analysis (Goanlysis) was performed to determine the functions 
of the differentially expressed genes.       
2.6 Statistical analysis 
2.6.1 Quantifying cryptococci – BMEC interaction 
 
Non-parametric Mann-Whitney U Test and Wilcoxon Signed Ranks Test were used to 
measure the significance of adherence at different conditions and time points. Mann-
Whitney U Test was applied to compare the means of test different setups, for 
instance comparing the mean association of encapsulated and acapsular strain to 
bEnd3 and or hCMEC/D3 cells. Wilcoxon Signed ranks test was applied to compare 
means of the same setup at different time points, for example comparing the mean 
association of encapsulated H99 strain or the acapsular mutant with endothelial cells 
after 2hrs and 4hrs of incubation at 37oC.  
2.6.2 Determining association between macrophage-cryptococci 
and patient clinical parameters  
 
Bivariate analysis was performed using Stata v11 (StataCorp, TX 77845 USA) to look 
for associations between Intracellular proliferation rate and uptake and clinical 
variables and outcome, using linear regression for continuous variables and logistic 
regression for categorical variables. 
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CHAPTER III: CRYPTOCOCCUS-BMEC INTERACTION 
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3.1 C. neoformans binding and internalization by BMEC 
 
Cryptococcal transcellular traversal of the blood-brain barrier (BBB) occurs through 
adherence and uptake of cryptococci by brain microvascular endothelial cells (Chang 
et al 2004; Vu et al 2009), but the rate at which this occurs is unknown. In order to 
quantify the binding and uptake of cryptococci by BMEC, we established an in vitro 
blood-brain barrier model using murine and human brain microvascular endothelial 
cell lines. The brain endothelial cells were grown in suitable media (see Methods) 
until they formed a complete mosaic of cell monolayer (Figure 6) and then exposed to 
cryptococci. The cryptococcal capsule, a major virulence factor of C. neoformans, has 
been implicated by various studies as being important in interactions with BMEC 
(Chang et al., 2004a; Charlier et al., 2005a; Charlier et al., 2005b; Fries et al., 2001; 
Guerrero et al., 2006; Ibrahim et al., 1995; Jain et al., 2006b), we therefore 
investigated the effect of presence or absence of the capsule on the rate of 
cryptococcal binding and uptake by BMEC. A large part of the results presented in 
this chapter and the methods used (Chapter II section 2.1) have already been 
published (Sabiiti and May, 2012). 
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Figure 6: Both murine and human brain microvascular endothelial cells form 
confluent cell monolayers  
A) The murine bEnd3 cell monolayer. B) The human hCMEC/D3 cell monolayer. 
Images taken with a phase contrast light microscope. 
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3.1.1 Association with and internalization by the murine brain 
endothelial cell line bEnd3 
 
We exposed the mouse brain endothelial cell line bEnd3 to wildtype C. neoformans 
H99 and its isogenic acapsular derivative, cap59 (De Jesus et al., 2010). The two 
strains were tested for their rate of binding and internalization by BMEC and whether 
the presence or absence of capsule has an effect on this interaction. After two hours of 
exposure to bEnd3 cells at 37oC, 8.8x103 (0.43%) of inoculated wild type (H99) 
cryptococci had adhered strongly to the endothelial layer, rising to 2.0 x 104 (1.2%) 
after four hours, P < 0.01. Similarly, 1.6x104 (0.8%) of the acapsular cryptococci had 
associated with bEnd3 cells at 2hr rising to 2.5x104 (1.23%) after four hours of 
incubation at 37oC, P < 0.01.  By using calcoflour staining to discriminate surface 
bound from internalised cryptococci, we determined that 3.1x103 (35% of associated) 
and 4.4x103 (28% of associated) wild type and acapsular cryptococci, respectively, 
had been internalised by 2 hours at 37oC, rising to 8.1x103 (40%) and 8.6x103 (35%) 
respectively by 4hrs, P < 0.01. The acapsular strain cap59 showed a slightly higher 
but not significant rate of association at 2hr, P = 0.1, which diminished by 4hr when 
both cap59 and H99 were equally associated with bEnd3 cells, P = 0.5. Importantly, 
for both strains, microscopic yeast cell counts and live CFU counts gave the same rate 
of association for both H99 and cap59, suggesting that there is no significant drop in 
cryptococcal viability upon adherence to or uptake by bEnd3 cells (Figure 7).  
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Figure 7: Binding and uptake of H99 and cap59 to the murine brain endothelial 
cells  
BEnd3 cells were exposed to wild type H99 and its acapsular derivative cap59 for 2hr 
and 4hr at 37oC.  (A) The rate of association (bound and internalized cryptococci) was 
determined both by microscopy and live CFU counts. The rate of association 
increased significantly in a time dependent manner, (P <0.01 for both strains). 
However, there was no difference in association of encapsulated H99 or acapsular 
cap59 cells (P = 0.1 and 0.5 at 2hr and 4hr respectively). (B) Internalization of the 
strains, H99 and cap59 by bEnd3 cells as determined by fluorescence microscopy. 
Internalized cryptococci (pre-stained with FITC) were distinguished from 
extracellular adherent ones by counter labelling with calcofluor white after infection. 
Intracellular cryptococci retained the FITC green signal while extracellular cells 
acquired the blue signal from calcofluor. The number of phagocytosed cryptococci 
increased significantly in a time dependent manner, (P < 0.01 for both strains). 
However, there was no difference in internalization of encapsulated H99 and 
acapsular cap59, (P = 0.5 and 0.8 at 2hr and 4hr respectively).  Error bars are standard 
error of the mean, n = 5 repeats. 
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3.1.2 Association and internalization by human brain endothelial 
cells, hCMEC/D3 
 
To test whether the rates of adherence and uptake that we had observed in bEnd3 cells 
were species specific, we repeated our analyses using the human brain endothelial 
derived cell-line, hCMEC/D3. As with bEnd3 cells, both microscopic and CFU counts 
showed that encapsulated H99 and its isogenic acapsular mutant cap59 associated and 
were engulfed at the same rate, P > 0.05 (Figure 8) at 2hr and 4hr of infection 
respectively. To determine whether the interaction varies from strain to strain, we 
tested a different pair of C. neoformans serotype D strains, encapsulated B3501 and 
its isogenic acapsular strain B4131. Like the H99/cap59 isogenic pair, both B3501 
and B4131 strains associated and were internalized at the same rate with hCMEC/D3 
cells P > 0.05 (Figure 9).  However, unlike bEnd3 cells, we observed a significant 
decrease over time in cryptococcal CFU counts for both strains.  Microscopic counts 
revealed that association and internalization for both strains increases with time of 
incubation, suggesting a loss of viability by cryptococci during association with 
hCMEC/D3 cells. One potential explanation for this result is that hCMEC/D3 cells 
may generate a more antimicrobial environment for cryptococci following uptake than 
that produced by bEnd3 cells.  In support of this, microscopic examination of infected 
endothelial cells labelled with Lysotracker (a reporter for acidic, mature phagosomes) 
(Figure 10) demonstrated that 50% of intracellular cryptococci in hCMEC/D3, but  
<10% in bEnd3 cells, were Lysotracker positive at 4hr of incubation. Thus bEnd3 
cells and hCMEC/D3 cells bind and engulf cryptococci at similar rates, but only 
hCMEC/D3 cells are able to significantly reduce cryptococcal viability following 
uptake.  
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Figure 8: Binding and uptake of H99 and cap59 to the human brain endothelial 
cells  
Like bEnd3 cells, hCMEC/D3 cells were exposed to the C. neoformans serotype A 
isogenic strains, wild type H99 and acapsular derivative cap59 for 2hr and 4hr at 
37oC.  Microscopic (Mic.) and live CFU counts were performed to determine the 
association and survival of cryptococci. (A) Association efficiency of H99 and cap59 
cryptococci with hCMEC/D3 cells. As opposed to microscopic counts, live CFU 
counts showed a time dependent decrease in the number of associated cryptococci by 
4hr of incubation, ! = P < 0.05 and !! = P <0.01 for H99 and cap59 respectively, 
suggesting a drop in viability of the hCMEC/D3 associated H99 and cap59 
cryptococci. There was no difference in association of encapsulated H99 and 
acapsular cap59, P = 0.7 and 0.6 at 2hr and 4hr respectively. (B) Internalization of 
encapsulated H99 and acapsular cap59 cryptococci by human brain endothelial cell 
line, hCMEC/D3 cells. The internalized cryptococci and extracellular adherent were 
determined as in Figure 7. As with association, the number of phagocytosed 
cryptococci increased significantly in a time dependent manner, P = 0.01 and <0.01 
for H99 and cap59 respectively. However, there was no difference in internalization 
of H99 and acapsular cap59 cryptococci, P = 0.5 and 0.8 at 2hr and 4hr respectively. 
Error bars are standard error of the mean, n = 6 repeats. 
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Figure 9: Binding and uptake of B3501 and B4131 to the human brain 
endothelial cells  
HCMEC/D3 cells were exposed to C. neoformans serotype D wild type B3501 and its 
isogenic acapsular mutant B4131 for 2hr and 4hr at 37oC.  Microscopic and live CFU 
counts were performed to determine the association and survival of cryptococci. (A) 
Association efficiency of B3501 and B4131 cryptococci with hCMEC/D3 cells. Like 
the H99-cap59 pair, live CFU counts showed a time dependent decrease in the 
number of associated cryptococci by 4hr of incubation, ! = P < 0.05, !! = P < 0.01 
for both B3501 and B4131. There was no difference in association by encapsulated 
B3501 and acapsular B4131, P > 0.05 at 2hr of incubation.  However, B4131 was 
significantly more associated, P = 0.02 (Microscopy) and <0.01 (CFU) by 4hr of 
incubation. (B) Internalization of encapsulated B3501 and its acapsular mutant 
derivative B4131 by hCMEC/D3 cells determined by fluorescence microscopy (Mic). 
The number of phagocytosed cryptococci increased significantly in a time dependent 
manner, P = 0.01 for both strains. However, there was no difference in internalization 
of B3501 and B4131, P = 0.5 and 0.2 at 2hr and 4hr respectively. Error bars are 
standard error of the mean, n = 6 repeats. 
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Figure 10: hCMED3/D3 internalized crytococci acquire the phagosomal marker, 
Lysotracter  
HCMEC/D3 cells were exposed to C. neoformans serotype A H99 (GFP-expressing) 
strain for 2 – 4hr and thereafter treated with lysotracker dye for 30min at 37oC 
followed by 10min treatment with calcofluor white at room temperature to label 
extracellular cryptococci. Images were taken within 1hr after treatment using 
multicolour fluorescence microscopy and x40 phase objective.  A) GFP signal 
(confirming that the observed particle is a cryptococcal cell). B) Absence of signal in 
the UV channel (calcoflour gives blue signal under UV light), indicating that the 
observed yeast cell is intracellular. C) The red channel showing that the observed 
internalized yeast cell has acquired lysotracker, which implies that is within acidified 
phagosome. D) The merged image showing the lysotracker-stained cryptococcus 
internalized by hCMEC/D3 cell.  
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3.1.3 Effect of opsonisation on Cryptococcus – BMEC association 
and internalization 
 
Since most individuals produce circulating antibodies to cryptococci by late childhood 
(Goldman et al., 2001b), we investigated whether opsonisation of cryptococci with 
antibody increases the association and internalization with brain endothelial cells.  
However, there were no significant differences between opsonised and non-opsonised 
yeast in either adherence or uptake at either time point tested, P > 0.05 (Figure 11), 
suggesting binding and uptake by brain endothelial cells is opsonin independent. 
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Figure 11: Effect of opsonisation on cryptococci binding and uptake by bEnd3 
cells  
Live (LV) and heat-killed (HK) H99 cryptococci were opsonised with mouse derived 
anti-capsule IgG antibody, 18B7 and the rate of adherence and internalization was 
determined by fluorescence microscopy.  (A) Association of opsonised (op) and non-
opsonised (Nop) cryptococci with bEnd3 cells. Rate of association of opsonised and 
non-opsonised H99LV cryptococci was similar, P = 0.8 and 0.4 at 2hr and 4hr 
respectively. Similarly, there was no difference between opsonised and non-opsonised 
heat-killed H99 cryptococci, P = 0.9 and 0.5 at 2hr and 4hr respectively. (B) Rate of 
internalization of opsonised and non-opsonised cryptococci internalized by bEnd3 
cells. The number of internalized H99LV cryptococci was similar, regardless of 
opsonisation status (P = 0.9 at both 2hr and 4hr). Similarly, there was no difference 
between opsonised and non-opsonised heat-killed H99 cryptococci, P = 0.5 and 0.4 at 
2hr and 4hr respectively. Error bars are standard error of the mean, n = 5 repeats. 
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3.1.4 Rate of association and internalization 
 
The rate of association and internalization of cryptococci by both murine and human 
cell-lines was less than 2% of the inoculum, an indication that this interaction is not a 
frequent event (Table 4). 
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Table 4: A summary of the percentage association and internalization of 
cryptococci by BMEC at different time points as determined by microscopic 
counts  
The percentages are calculated as ratio of the number of cryptococci associated with - 
and or internalized by – BMEC (bEnd3 or hCMEC/D3) to the original cryptococcal 
inoculum (2x106 yeast cells). Association (Assoc.) equals to the total number of 
cryptococci adhered to – and internalized by – BMEC whereas internalization 
(Intern.) is the number of cryptococci phagocytosed by BMEC. LV = Live and HK = 
Heat killed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
BMEC Strain
% Assoc. at 
2hr
% Intern. 
at 2hr
% Assoc. 
at 4hr
% Intern. 
at 4hr
bEnd3 H99LV 0.44 0.15 1.03 0.4
H99HK 0.46 0.11 0.62 0.13
cap59LV 0.79 0.22 1.23 0.43
cap59HK 0.24 0.1 0.48 0.19
hCMEC/D3H99LV 0.51 0.28 0.68 0.37
H99HK 0.49 0.19 0.73 0.28
cap59LV 0.47 0.23 0.77 0.37
cap59HK 0.43 0.21 0.57 0.28
B3501LV 0.37 0.21 0.64 0.42
B4131LV 0.53 0.21 0.91 0.4
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3.1.5 Effect of IFN-γ  induction on Cryptococcus – BMEC 
association and internalization 
 
The inflammatory cytokine IFN-γ has previously been shown to mediate changes in 
brain endothelial behaviour (Dietrich, 2002; Lachenmaier et al., 2011). Thus we 
considered whether IFN-γ mediated inflammation might increase cryptococcal uptake 
by BMEC.  However, treatment of bEnd3 cells with either 100U or 500U of mouse 
IFN-γ 12hr prior to infection did not significantly alter uptake of either wild type or 
acapsular cryptococci at either time point tested (Figure 12). 
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Figure 12: Effect of IFN-gamma induction on binding and uptake of cryptococci 
by BMEC  
Murine brain endothelial cells (bEnd3) cells were induced with different 
concentrations (100U and 500U) of IFN-γ 24hr prior to exposure to encapsulated H99 
(A) and acapsular mutant cap59 (B) cryptococci. Non-stimulated bEnd3 cells (IFN-γ 
NIL) were used as a negative control. IFN-γ did not have effect on the rate of 
association since both induced and non-induced (control) bEnd3 cells showed the 
same level of binding encapsulated and acapsular cryptococci. Error bars are standard 
error of the mean, n = 3 repeats. 
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3.1.6 Viability of cryptococci is not a prerequisite for association 
and internalization by BMEC 
 
We next investigated whether the uptake of cryptococci into BMEC requires active 
signals from the pathogen.  However, heat-killed H99 retained the ability to bind and 
enter both mouse bEnd3 and human hCMEC/D3 cells at a similar rate to live yeast. 
Although viable cryptococci showed higher association efficiency in bEnd3 cells, 
there was no significant difference between internalization of viable and heat-killed 
cryptococci in both bEnd3 and hCMEC/D3 cells. Thus BMEC invasion is most likely 
a passive process that occurs without active signals from the yeast cell (Figure 13).  
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Figure 13: Effect of viability on binding and uptake of H99 and cap59 strains by BMEC  
Heating for 15min at 65oC prior to infection killed H99 and cap59 cryptococci.  Brain microvascular cells (BMEC), bEnd3 and or hCMEC/D3 
cells were exposed in parallel to live (LV) and heat-killed (HK) cryptococci for 2hr and 4hr at 37oC and the number of bound and internalized 
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cryptococci was determined by fluorescence microscopy. (A and C): Association efficiency of live and heat-killed H99 or cap59 cryptococci by 
bEnd3 and hCMEC/D3 cells respectively. There was no difference in association of viable H99 and cap59 cryptococci with hCMEC/D3 cells at 
either time point, P > 0.05. However, viable cryptococci were more associated than non-viable ones both 2hr and 4hr (for cap59) and 4hr (for 
H99) of incubation with bEnd3 cells, P <0.01. (B and D): Internalization efficiency of LV and HK H99 and cap59 cryptococci by bEnd3 and 
hCMEC/D3 cells. Both live and heat-killed cryptococci showed a time dependent increase in phagocytosis by both bEnd3 and hCMEC/D3 cells, 
however the rate of phagocytosis did not vary between the viable and non-viable cryptococci in both cell-lines, P >0.05 at both 2hr and 4hr of 
incubation. Error bars are standard error of the mean, n = 5 repeats. 
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3.1.7 Viability of BMEC 
 
To verify that the observed binding occurred in association with endothelial cells, and 
not due to indirect sequestration of yeast cells, bEnd3 and hCMEC/D3 monolayers 
were killed by paraformaldehyde fixation prior to cryptococci inoculation. For all 
conditions, cryptococcal binding was reduced by between one and two log orders, 
indicating that that viable endothelial cells were responsible for the observed 
cryptococcal association (Figure 14). 
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Figure 14: Binding to fixed brain endothelial cell monolayer (negative control)  
To verify that the observed binding occurred in association with endothelial cells, and 
not due to indirect sequestration of yeast cells, bEnd3 and hCMEC/D3 monolayers 
were killed by paraformaldehyde fixation prior to cryptococci inoculation. For all 
conditions, cryptococcal binding was reduced to almost zero compared to the positive 
controls, H99 versus live hCMEC/D3 cells (green bars) and H99 versus live bEnd3 
cells (pink bars), indicating that viable endothelial cells were responsible for the 
observed cryptococcal association. Error bars are standard deviation of the mean, n = 
2 repeats. 
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3.2 Chapter III summary 
 
To infect the brain, C. neoformans has to cross the normally impermeable blood-brain 
barrier (BBB). Transcytosis is one of the mechanisms put forward to explain 
cryptococcal traversal of the BBB. Brain microvascular endothelial cells (BMEC) are 
the major component of the blood-brain barrier and hence define the transport of 
substances into the brain. C. neoformans has been shown to take advantage of the 
cellular endocytosis transport apparatus by which cryptococci are phagocytosed by 
BMEC on the luminal side of the BBB and exocytose on the basal side into the brain 
tissue. We therefore asked, at what rate does the adherence and internalization of 
cryptococci by BMEC occur and does the capsule influence this rate? Using both 
murine (bEnd3) and human (hCMED/3) brain endothelial cells we have shown that 
the binding and uptake of cryptococci to BMEC is an infrequent event characterized 
by smaller number of cryptococci at a given time but one that increases with time as 
demonstrated by the significant rise of cryptococci associated with BMEC from 0.43-
0.8% at 2hr to 1.2-1.23% at 4hr. To determine whether the capsule influences the rate 
of binding and uptake, we made use of 2 pairs of isogenic strains of encapsulated and 
acapsular C. neoformans strains, H99/cap59 and B3501/B4131. We have shown that 
there was no difference in binding and uptake by BMEC of encapsulated and 
acapsular cryptococci, suggesting that the binding and uptake of cryptococci by brain 
microvascular endothelial cells is independent of the capsule. Taken together, the low 
rate of cryptococcal association with BMEC and the capsule independent interaction 
suggests that C. neoformans most likely uses multiple means to associate with and 
penetrate the BBB mediated by non-capsule molcules such as hyaluronic acid. Heat 
killing cryptococci did not alter the rate of binding and uptake, which indicates that 
the molecules involved in BMEC-cryptococci interaction are heat resistant.  Unlike 
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the pathogen, viability of the endothelium is preliquisite to cryptococcal adherence 
and internalization. 
 
Unlike macrophages, antibody opsonisation does not enhance binding and uptake of 
cryptococci by BMEC, which suggest that BMEC do not possess FC receptor 
required for binding IgG opsonized molecules, the reason why opsonisation did not 
enhance binding and uptake. Alternatively, other opsonisation mechanisms such as 
compliment could be important for this intearction. Furthermore BMEC induction 
with IFN-γ, a known inducer of cell surface adhesion molecules (e.g Intercellular cell 
adhesion molecule, ICAM; Vescular cell adhesion molecule, VCAM), did not 
increase binding and uptake of cryptococci. Cell surface adhesion molecule 
expression by an induced endothelium is most likely important for cell-to-cell 
adhesion such as phagocyte to endothelim and hence would promote intracellular 
pathogen traversal of BBB rather than free extracellular cryptococci.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 102 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER IV: MACROPHAGES AND CLINICAL CRYPTOCOCCUS 
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Cryptococcal parasitism of macrophages is well documented (Alvarez and 
Casadevall, 2007; Feldmesser et al., 2001b; Ma et al., 2007; Ma et al., 2009) and has 
been shown to mediate the dissemination of cryptococci into the brain in a murine 
model of cryptococcosis (Charlier et al., 2009). By studying the C. gattii isolates from 
the so-called ‘Vancouver Island Outbreak’, our laboratory has previously 
demonstrated that isolates with high intracellular proliferation rates in macrophages 
were hypervirulent in a mouse model of infection (Ma et al., 2009). These 
observations confirmed the importance of macrophage – Cryptococcus interactions in 
the pathogenesis of cryptococcosis. While the Vancouver outbreak was caused by C. 
gattii and mainly affected immunocompetent people (often presenting with 
pulmonary cryptococcosis), no such studies have been undertaken on cryptococcal 
isolates from HIV-associated cryptococcosis, which is mainly caused by C. 
neoformans. Thus we studied 47 C. neoformans clinical isolates from cerebral spinal 
fluid (CSF) of HIV-associated cryptococcal meningitis patients, analyzing the rate at 
which they are engulfed by macrophages and their subsequent rate of intracellular 
proliferation. Isolates were also characterized for melanin production, capsule 
expression and iron utilization, traits required for C. neoformans intracellular survival 
and dissemination in the host. Isolates were also investigated for their survival and 
association with phagocytes in fresh whole blood from healthy donors. Finally, by 
studying gene expression, we sought to decipher the genetic factors underlying the 
difference in cryptococci phagocytosis by macrophages. 
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4.1 Rate of uptake (phagocytosis) and intracellular 
proliferation rate (IPR)  
 
Murine derived J774 macrophages were infected with cryptococci at an infection ratio 
of 1:10 and incubated for 2, 18, 24, and 48hrs at 37oC with 5% CO2. At each time 
point, macrophages were thoroughly washed to remove extracellular cryptococci and 
then lysed to release intracellular cryptococci, which were counted using a 
haemocytometer. The rate of uptake was calculated as the number of cryptococci 
phagocytosed by macrophages at two hours of incubation and intracellular 
proliferation rate was determined as the ratio of intracellular cryptococci at 18hr to 
intracellular cryptococci at 2hr. Isolates exhibited an array of uptake rates, Median 
(range) = 422 (93 – 1530) cryptococci/ 1µL lysate (Figure 15) or 4.22 (0.93 – 15.3) 
cryptococci per macrophage.  Intracellular proliferation rates were similarly variable 
(Figure 16), Median (range) =2.77 (1.38 – 4) in murine macrophages.  
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Figure 15: Cryptococci uptake rates by J774 macrophages  
The murine macrophage-like cell-line, J774, were exposed to C. neoformans clinical isolates at an infection ratio of 1:10 in quadruplicates in 24 
well tissue culture plates for two 2hr at 37oC with 5% CO2.  After the two-hour incubation, macrophages were extensively washed to remove 
extracellular cryptococci. Macrophages in one of the wells were then lysed to release intracellular cryptococci, which were counted by 
haemocytometer and recorded as number of cryptococci per 1 µL lysate. The remaining wells were further incubated to determine intracellular 
growth. Rate of uptake for each isolate was determined as the number of cryptococci internalized by macrophages within 2hr of incubation. 
Isolates were taken up at different rates ranging from the highest, CCTP13 = 1.383 x103 cryptococci per 1 µL lysate to the lowest, CM50 at 
0.93x102 cryptococci per 1µL lysate. The error bars are standard error of the mean (n = 4 – 7 repeats).
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Figure 16: Intracellular proliferation rates of clinical isolates in J774 macrophages  
Following the two 2hr exposure during which the rate of uptake was determined, remaining cultures were incubated at 37oC with 5% CO2 for 18-
, 24- and 48hr. At each time point, extracellular cells were removed by washing and macrophages lysed to release intracellular cryptococci for 
counting with haemocytometer. Intracellular proliferation rate (IPR) for each isolate was determined as ratio of crypotococci at 18hr to 
cryptococci at 2hr. All isolates had IPRs above 1, which affirms C. neoformans’ ability to proliferate inside macrophages. Compared to high 
uptake isolates, the low uptake isolates generally had high IPR (highest uptake isolate CTTP13 IPR = 2.2 while lowest uptake isolate CM50 IPR 
= 5.83). Error bars are standard error of the mean (n = 4 – 7 repeats).   
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To test whether this variation was species specific, a selection of high and low uptake 
isolates were tested in human primary macrophages.  This analysis showed a 
consistent pattern of uptake with J774 macrophages (Figure 17).  
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Figure 17: Cryptococci uptake rates by human primary macrophages  
A panel of high and low uptake isolates in murine J774 macrophages were selected 
and tested for uptake in human monocyte-derived macrophages. Infection ratio, 
interval of exposure and determination of rate of uptake were conducted as described 
in Figure 15. As with J774 macrophages, the high uptake isolates (CTTP13, CTTP3, 
CCTP10, CTTP2) were better phagocytosed by human macrophages than the low 
uptake isolates (RCT60, RCT33, RCT7, IFN16 and CM36), suggesting that strain-
dependent variation in ‘ease of phagocytosis’ is conserved between species. Error bars 
are standard error of the mean (n = 5 repeats). 
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4.1.1 Cryptococci uptake by macrophages is inversely correlated 
with IPR 
  
In both cell types, cryptococci uptake and intracellular proliferation rate were 
negatively correlated, such that strains with a high basal rate of uptake showed lower 
intracellular proliferation rates (Figure 18).  
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Figure 18: The association between uptake and Intracellular proliferation rate 
(IPR)  
A regression analysis of isolates’ rates of uptake and intracellular proliferation rates 
was performed to determine the correlation between these two variables. Uptake was 
inversely correlated to IPR, implying that high cryptococcal uptake by macrophages 
slows down the rate at which these cryptococci subsequently proliferate. 
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4.1.2 High uptake isolates better phagocytosed by macrophages in 
absence of opsonin  
 
Opsonisation enhances the rate of cryptococcal phagocytosis by macrophages 
(Bolanos and Mitchell, 1989b; Mukherjee et al., 1995b; Vecchiarelli et al., 2002); 
hence we tested the cryptococcal uptake by macrophages in the absence of 
opsonisation.  For both high and low uptake strains, the rate of uptake was reduced by 
≥50%, although this was more profound for the low uptake isolates (Figure 19). The 
internalization of high uptake isolates in absence of opsonin was significantly higher 
than that of low uptake isolates, P < 0.01. 
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Figure 19: Rate of cryptococci uptake in absence of opsonin 
A panel of high and low uptake isolates in murine J774 macrophages were selected 
and tested for uptake in absence of the opsonin. Infection ratio, interval of exposure 
and determination of rate of uptake were carried out as described in Figure 12A. Rate 
of uptake was reduced for both sets of isolates but the high uptake isolates (CTTP13, 
CTTP3, CCTP30, CCTP10, CTTP2) were still better phagocytosed than the low 
uptake isolates (RCT60, RCT33, RCT7, IFN16 and CM36). Error bars are standard 
error of the mean (n = 4 repeats).  
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4.2 Correlation of uptake and IPR with patient clinical 
parameters  
4.2.1 Rate of uptake positively correlates with patient fungal 
burden  
 
Uptake and intracellular proliferation profiles were analyzed against patient CSF 
parameters (glucose, protein, white blood cell count, pro-inflammatory cytokines and 
fungal burden) and clinical outcome to look for potential associations. Uptake was 
weakly positively correlated with high CSF fungal burden (Figure 20). In addition, 
there was seemingly strong correlation between uptake and CSF protein (r2 = 0.1283, 
P = 0.0134), lymphocyte count (r2 = 0.1627, P = 0.0081), white cell count (r2 = 
0.1592, P = 0.0055) driven by one high uptake isolate CCTP13 and disappears when 
the isolate is taken out of the analysis. However, the positive trend of association 
between high uptake and high CSF lymphocyte count; white cell count is retained 
when the data is categorized according to presence of inflammation (>5 white blood 
cells per mm3 CSF, n = 23 patients) or absence of inflammation (≤5 white blood cells 
per mm3 CSF, n = 24 patients).  
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Figure 20: The correlation between rate of cryptococci uptake and patient CSF 
fungal burden  
Linear regression was used to determine the association between uptake of isolates 
and baseline (before antifungal treatment) fungal burden of the patients. Patient fungal 
burden was determined by quantitative cryptococcal cultures of patient derived CSF 
as CFU/ml from which the log10 was calculated (Fungal burden data provided by 
Tihana Bicanic et al, St. Georges’ University of London).   
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4.2.2 IPR inversely correlates with CSF fungal burden, CrAg and 
TNF-α  
 
In contrast, intracellular proliferation (IPR) was weakly negatively correlated with 
CSF fungal burden, cryptococcal antigen (CrAg) and TNF-α levels (Figure 21, 22 and 
23 respectively). The IPR correlations with patient CSF parameters are to some extent 
inverse of the positive association between uptake and CSF patient parameters.  
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Figure 21: The association of IPR and CSF fungal burden  
There was an inverse correlation between IPR and CSF fungal load. The association is 
particularly driven by one high IPR strain CM50, IPR = 5.83. 
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Figure 22: Association of IPR and CSF cryptococcal antigen (CrAg)  
CrAg titre is the detection and measurement of soluble cryptococcal capsule in CSF 
or any other body fluids such as blood and urine. The higher the IPR, the lower the 
CrAg titre. Like fungal burden, the IPR – CSF CrAg association is driven by isolate 
CM50 (IPR = 5.83) and is lost when CM50 is removed from the analysis. 
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Figure 23: The correlation between IPR and CSF TNF-alpha profile  
Linear regression analysis was performed on both uptake and IPR and CSF-cytokine 
levels. A significant negative correlation was found between IPR of the 46 including 
41 African origin isolates and 5 Thailand isolates and baseline CSF TNF-! levels. 
The 6th Thailand isolate CM50 was the outlier and was not included in the analysis. 
The CSF TNF-! profile was previously determined by Immunosorbent enzyme linked 
assay (ELISA) of patient CSF (Bicanic et al, St Georges University of London).  
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4.3 Melanisation and capsule expression of the clinical 
isolates 
4.3.1 Melanisation 
 
Melanin is an antioxidant and therefore essential for C. neoformans to survive the 
lethal oxygen and nitrogen reactive species produced inside macrophages. We 
investigated the rate at which isolates produced melanin from the melanin precursor, 
L-DOPA (Figure 24), and tested this rate for association with cryptococcal uptake and 
IPR. High uptake isolates were faster melanizers that low uptake ones. Rate of 
melanization was positively correlated with uptake (r2 = 0.1, P = 0.0293), implying 
that unlike low uptake isolates, high uptake isolates had higher ability to produce 
melanin (Figure 25). 
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Figure 24: C. neoformans melanisation on L-DOPA agar  
A) Non-melanised colony. B) Melanised colony. Both colonies were observed for 15 
days with daily recording of browning rate. 
 
 
 
 
 
 
 
 
 
 
 
A B 
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Figure 25: Association between uptake and melanin formation  
Rate of melanin formation by isolates was determined by growth on L-DOPA agar. 
The melanisation rates were analyzed against uptake and IPR using linear regression. 
Rate of melanin formation was positively correlated with uptake and vice versa for 
IPR. 
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Passaging isolates in macrophages significantly increased the rate of melanisation P = 
0.0002, suggesting that intracellular environment most likely upregulates expression 
of genes involved in melanin formation (Table 5).  
 
Isolate MR Extra. MR Intra. 
CCTP13 0.83 1.25 
IFN1 0.33 1.13 
IFN2 0.5 0.75 
IFN4 0.83 1.7 
IFN5 0.42 0.75 
IFN6 0.71 0.75 
IFN11 0.71 1.67 
IFN12 0.5 1.25 
IFN15 0.63 0.9 
IFN16 0.39 0.75 
IFN17 0.63 0.9 
B3501 0.53 0.75 
MIN 0.33 0.75 
MAX 0.83 1.7 
MEDIAN 0.58 1.23 
P VALUE 0.0002 
 
Table 5: Effect of intracellular environment on melanisation rate  
A set of clinical isolates and one laboratory reference C. neoformans serotype D strain 
B3501 were passaged in J774 macrophages for 24hr prior to melanization assay.  
Macrophages were washed to remove extracellular cryptococci and intracellular 
cryptococci released from macrophages by water lysis. 5µL of the lysate for each 
isolate was inoculated onto L-DOPA agar to determine the rate of melanin formation. 
By Mannwhitney U test, the intracellular melanisation rates (MR intra.) were 
significantly higher than the extracellular melanisation rates (MR extra.), P = 0.0002. 
Extracellular melanisation rate implies MR determined by inoculating L-DOPA with 
cryptococci directly from YPD culture medium. 
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4.3.2 Capsule expression 
 
The capsule is a major virulence factor of C. neoformans and has been demonstrated 
to function as an antiphagocytic factor as well as an aid for intracellular survival 
(Zaragoza et al., 2008). We measured the capsule diameter of each isolate following 
growth in capsule induction medium and the capsule sizes were analyzed against the 
rate of uptake and IPR in macrophages. High uptake isolates exhibited low capsule 
expression as opposed to low uptake isolates with an inverse correlation with rate of 
uptake by macrophages (Figure 26).  There was a trend but not significant positive 
association between capsule diameter and IPR (Figure 27). 
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Figure 26: Association between uptake and capsule expression  
Capsule diameters were determined by Image J measurement following growth of 
isolates in capsule induction medium. Capsule diameter (µm) was inversely correlated 
with uptake, implying that the high uptake isolates possess smaller capsules than low 
uptake isolates.  
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Figure 27: Association between IPR and capsule expression  
Capsule diameters were determined by Image J measurement following growth of 
isolates in capsule induction medium. Capsule diameter (µm) was not significantly 
correlated with IPR but there was a trend of positive correlation between high IPR and 
high capsule diameter.  
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4.2.3 Iron utilization 
 
Iron is important for C. neoformans pathogenicity because iron is crucial for 
elaboration of major virulence factors, capsule and melanin (Jung et al., 2006) In the 
human host, iron exists largely associated with intracellular proteins, such as 
haemoglobin and ferritin, or extracellular proteins, transferrin and lactoferrin, leaving 
only a very limited amount of free iron (Perkins-Balding et al., 2004). However, iron 
acquisition is essential for both bacterial and fungal pathogens’ growth and 
elaboration of virulence factors (Jung and Kronstad, 2008; Schaible and Kaufmann, 
2004). We therefore investigated a selection of the high and low uptake isolates for 
their ability to grow under iron-limited conditions and to utilize either transferrin or 
heme as the only source of iron. Both high and low uptake isolates grew poorly on 
low iron medium and much lower compared to the laboratory reference strain H99 
(Figure 28A). High uptake isolates showed preferentially better growth on transferrin 
than the low uptake isolates, P = 0.0408 (Figure 28C). On the other hand, low uptake 
isolates utilized well on heme but not significantly better than high uptake isolates, P 
= 0.0932 (Figure 28D). All isolates showed high growth rates in rich medium YPD, 
however, the high uptake isolates’ rates of growth were significantly higher than the 
low uptake ones P = 0.026 (Figure 28B). Growth rate data for individual isolates is 
given in Appendix 3.    
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Figure 28: The growth phenotype of high and low uptake isolates in low iron 
conditions 
Growth phenotypes of high uptake  (n = 5 isolates) and low uptake (n = 6 isolates) 
were compared to that of the laboratory reference strain, H99. Prior to the assay, the 
iron reserves of all trains were reduced by 3-day growth in low iron medium. 
Cryptococci were then harvested and grown for 7 days in low iron medium (Lim), 
low iron medium with - transferrin as the only source of iron, heme as only source of 
iron); or in rich medium (YPD) as a control. Aliquots were taken every 24hr and 
plated for CFU counts, which were used to plot growth curves. Rate of growth was 
determined as the slope of the exponential growth curve for each isolate. A) Growth 
rate on low iron medium with both high and low growing poorly compared to H99. B) 
All isolates grew well in rich medium YPD with high uptake isolates performing 
better than H99.  C) Growth rate on transferrin as source of iron, high uptake isolates 
grew better than low uptake isolates. D) Growth rate on heme as source of iron, low 
uptake isolates grew better on than high uptake. Compared to clinical isolates, H99 
grew extraordinarily well on in low iron conditions and on transferrin and heme as 
sources of iron. High uptake isolates grew significantly better on transferrin than low 
uptake isolates and vice versa on heme. Both H99 and clinical isolates grew well on 
rich medium YPD. Error bars are standard error of the mean (n = 3 repeats).   
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4.4 Cryptococci survival and association with phagocytes in 
human whole blood 
4.4.1 Survival in whole blood 
 
The association between phagocyte-Cryptococcus interaction and CSF fungal burden 
may potentially be explained by the ability of cryptococci to exploit circulating 
phagocytes to disseminate to the brain.  We therefore investigated the ability of both 
high and low uptake isolates to survive and associate with phagocytes in whole blood 
taken from healthy donors and infected within 5-10min from bleeding. 1 ml of blood 
was inoculated with a predetermined (8.73 x 103 CFU/ml by PBS plating) number of 
cryptoccocci per isolate and incubated at 37oC with minimal rotation for eight hours. 
At regular time points, 100 µl aliquots of the culture were plated on YPD agar and 
viable cryptococci determined as colony forming units.  All isolates showed reduced 
viability after exposure to whole blood, with some being reduced to less than half the 
original inoculum within the first 10 – 30 min of exposure. After the initial hour of 
incubation there was little subsequent decrease in fungal CFU/ml (average of 6 x 103), 
which likely indicates the loss of unstable antifungal molecules (e.g. complement 
proteins) from blood after prolonged incubation (Figure 29). 
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Figure 29: Survival of high uptake and low uptake isolates in whole blood from 
healthy donors across a time period of 8hrs 
Whole blood was inoculated with 104 yeast cells of which 8.73x103 were determined 
viable through plating on YPD agar. The highest cryptococcal killing effect occurred 
within the first 10 – 30 min of which high uptake isolates (HIU, black bars, n = 4), 
survived significantly better than Low uptake isolates (LIU, black bars, n = 5), P = 
0.01. From 1hr and on wards both HU and LU cryptococci survived at a relatively 
constant rate throughout the 8hr period with HUI showing a trend of better survival 
than LUI. Error bars are standard error of the mean, n = 6 donors. 
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4.3.2 Association with phagocytes in whole blood 
 
We further investigated whether cryptococci were associated with phagocytes in 
whole blood and whether this occurred at the same rate for the low and high uptake 
isolates. Following 30 – 60 min of infection with FITC stained cryptococci, 
erythrocytes were removed by lysis and the remaining leukocyte population was 
analyzed by flow cytometry for association with cryptococci. At 60min, 2 – 4 % and 4 
– 14% cryptococci were associated with monocytes and neutrophils respectively. 
However, there was no difference between low and high uptake cryptococci in 
association with the two sets of phagocytes 60 min (Figure 30 and 31). 
 
 
 
 
 131 
 
Figure 30: Percentage association of cryptococci with monocytes in whole blood  
Fresh whole blood from healthy donors was incubated with FITC stained isolates and 
cryptococci (104 cells per 1ml of whole blood) for 60min. By flow cytometry the 
cryptococci associated with monocytes were determined using forward and side 
scatter. Unlike macrophages, Low uptake isolates (LUI), n = 5 exhibited higher but 
not significant rate of association with monocytes than High uptake isolates (HUI), n 
= 4. The high rate of association observed in the LUI is driven by isolate CM36 (See 
Appendix 3: Plot of all isolates). Error bars are standard error of the mean (n = 4 
donors). 
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Figure 31: Percentage association of cryptococci with neutrophils in whole blood 
Fresh whole blood from five healthy donors was incubated with FITC stained 
cryptococci (104 cells per 1ml of whole blood) for 60min. By flow cytometry the 
cryptococci associated with monocytes were determined using forward and side 
scatter. Like monocytes, Low uptake isolates (LUI), n = 5 exhibited higher but not 
significant rate of association with neutrophils than High uptake isolates (HUI), n = 4. 
The high rate of association observed in the LUI is driven by isolate CM50 (See 
Appendix 4: Plot of all isolates). Error bars are standard error of the mean (n = 4 
donors). 
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4.5 Gene expression and cryptococci uptake by macrophages 
 
To determine the genes that underly the difference in cryptococci uptake by 
macrophages, we tested 2 sets of isolates (4 high uptake and 4 low uptake isolates) for 
differential gene expression using RNAsequencing. Both high and low uptake isolates 
plus the reference strain H99 (Serotype A C. neoformans var. grubii, Cnag) were 
propagated in a pre-phagocytosis medium and RNA extracted for transcriptome 
sequencing. All sequences were aligned to the reference H99 genome yielding an 
average unique mapping rate of 81.8%. Pairwise comparison between isolates and 
H99 yielded between 776 – 2311 differentially expressed (DE) genes of which low 
uptake isolates had a slightly more DE genes to H99 than the high uptake isolates 
(Appendix 5).  Sequence alignments betweem the high and low uptake isolates 
yielded a total of 6846 informative genes (genes that have atleast average reads across 
two samples in the comparison). By Fisher’s exact test and filtering with absolute 
log2 fold change larger than 1 and 0.5% false discovery rate (q-value), 8 genes were 
found significantly differentially expressed between the high uptake and low uptake 
isolates (Figure 32).  
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Figure 32: Differentially expressed genes between the high uptake and low 
uptake isolates  
RNA was extracted from a set of high uptake (black bars) and low uptake (white bars) 
isolates before phagocytosis assay. By RNAsequencing 8 differentially expressed 
genes were determined of which 3 (CNAG 017040, CNAG 04245, CNAG 07945) are 
more expressed in the High uptake isolates whilst 5 (CNAG 01781, CNAG 07313, 
CNAG00127, CNAG 05632 and CNAG00588) were more expressed in low uptake 
isolates, P = <0.01 in all the 8 genes. Error bars are standard error of the mean. Eight 
isolates in total of which n = 4 for each set of isolates (high uptake and low uptake). 
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Out of the 8 differenntially-expressed genes, 3 (CNAG_04245, CNAG_05632 and 
CNAG_00588) had known function (Chinase, Mannose-6-phosphate receptor repeat 
and Racin superfamily respectively) Table. 
 
GeneID& ProtID& Prot&Function&
CNAG_01781* AFR97983.1|* None*
CNAG_07043* AFR98755.1|* None*
CNAG_07313* AFR92263.1|* None*
CNAG_04245* AFR96977.1* Chitinase*
CNAG_07945* AFR98751.1* None*(cystein*dioxygenase)*
CNAG_00127* AFR92264.1*
None*(but*present*in*C.#gattii*and*
Myxococcus)*
CNAG_05632* AFR99063.1* MannoseI6Iphosphate*receptor*repeat*
CNAG_00588* AFR92718.1* Ricin*superfamily*
 
Table 6: Differentially expressed genes and their protein function  
Genes CNAG_04245, CNAG_05632 and CNAG_00588 encode Chitinase, Mannose-
6-phosphate receptor repeat and Ricin superfamily. No known protein function 
encoded by genes CNAG_01781, CNAG_07043 and CNAG_07313; CNAG_07945 is 
thought to encode cysteine dioxgyenase while CNAG_00127 is present in C. gattii 
and Myxococcus. 
&
&
&
&
&
&
&
&
&
&
&
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4.6 Chapter IV Summary 
 
The role of phagocytes in the pathogenesis human cryptococcosis remains a critical 
question to answer. The study of C. gattii isolates in our laboratory demonstrated that 
high Intracellular proliferation rate in macrophages is correlated with hypervirulence 
in a mouse model of cryptococcosis (Ma et al., 2009). In this chapter, we have shown 
that there is a link between macrophage – Cryptococcus interaction phenotype and 
patient clinical phenotype. By studying the uptake (phagocytosis) and Intracellular 
proliferation rates of C. neoformans isolates in macrophages, we show that there is 
association between high cryptococci uptake by macrophages and patient CSF fungal 
burden. In addition we demonstrate that Intracellular proliferation rate (IPR) is 
negatively correlated with patient CSF fungal burden, crytococcal antigen titre and 
levels of TNF-α. Uptake and IPR are inversely correlated implying that high uptake 
isolates have low IPR. The inverse relationship also implies that parameters like 
crytococcal antigen titre and levels of TNF-α could be positively correlated with 
uptake. Taken together, rate of cryptococci uptake by macrophages stands out as the 
positively associated factor with patient clinical phenotype. Therefore, the question is 
what could be the link between cryptococci uptake by macrophages and 
pathophysiology of cryptococcal meningitis? It could mean that either highly 
phagoctosed isolates have a high chance to dessiminate from the lungs (initial site of 
infection) to the brain using macrophages as Trojan horses or high uptake isolates are 
endowed with unique virulence traits that make them to efficiently survive and 
dessiminate in the host. 
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Testing the isolates by the known major virulence factors, capsule and melanin, we 
found that the high uptake isolates were high melanin formers but less capsulated 
demonstrated by the positive and inverse correlations between uptake and rate of 
melanin formation and capsule diameter respectively. This result suggests that the 
smaller the capsule the higher the rate of phagocytosis and rapid melanin formation is 
most likely crucial for surviving in the host and particulary the hostile intracellular 
environment. Passaging a set of isolates in macrophages significantly increased the 
rate of melanin formation implying that components of melanin formation pathway 
are vital and thus are highly expressed during intracellular survival. Efficient nutrient 
acquisition is important for pathogen survival in the host. By analysing Iron source 
utilization profiles, we show that high uptake isolates survive better in low iron 
medium and more efficient utilizers of transferrin as only Iron source than the low 
uptake isolates. The brain tissue is rich in transferrin (Dwork et al., 1988) and perhaps 
that is why high uptake isolates have high CSF fungal load because they proliferate in 
brain tissue rich in Transferrin. Exvivo analysis of high uptake and low uptake 
isolates in whole blood from healthy donors showed a significantly higher survival 
rate by high uptake isolates than low uptake ones in the first 10 - 30min of exposure 
to blood which faded with increase incubation time. This suggests that the crucial 
blood antimicrobial factors may have a short active life outside the donor and hence 
the defining killing effect occurs in the first few minutes. Interestingly, low uptake 
isolates show higher but not significant association with phagocytes in blood than the 
high uptake ones. This higher association efficiency particulary with neutrophils 
might contribute to the observed low survival in whole blood. Alternatively, it could 
be that the mechanism of association with blood phagocytes is different from tissue 
 138 
macrophages and hence the discrimination between high and low uptake most likely 
occurs at the level of alveolar macrophages in the lungs.  
 
The fact that there was consistent trend of cryptococci uptake by both mouse and 
human macrophages indicate that there is underlying genetic factors driving the 
difference in phagocytosis. Prephagocytois differential gene expression analysis 
revealed eight differentially expressed genes between high uptake and low uptake 
isolates. Three out of the eight genes encode proteins Chitinase, Mannose-6-
phosphate receptor repeat and Ricin. Although these proteins might be important to 
Cryptococcus in certain aspects, none of them has been implicated in modulation of 
phagocytosis. Chitinase degrades chitin, a crucial component of the fungal cell wall 
and is thought to maintain the dynamic state of the fungal cell wall during growth and 
has been shown to be crucial sexual reproduction in C. neoformans  (Baker et al., 
2009) and also induces allergic inflammation in pulmonary cryptococcosis (Vicencio 
et al., 2008). Mannose-6-phosphate receptor is implicated in vesicle transport and 
endosome maturation (Qin et al., 2011) whilst ricin is a toxic lectin produced by 
caster plants but no known function has yet been described for C. neoformans. Genes 
underlying known antiphagocytic factors such as the capsule, antiphagocytic protein 1 
and GATA family transcription factor (Gat201) were not differentially expressed 
between the two sets of isolates. This may mean that either the observed DE genes 
affect phagocytosis in ways that aren’t yet illucidated or that pro-/anti-phagocytic 
gene expression occurs when cryptococci are exposed to macrophages and not before 
(in a macrophage free prephagocytosis medium), a reason why the difference in these 
genes could not be detected.  
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CHAPTER V: DISCUSSION 
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5.1 C. neoformans and the brain-microvascular endothelial 
cells 
 
The mechanism by which C. neoformans associates with – and penetrates - the BBB 
remains a critical question in understanding the pathogenesis of CNS cryptococcosis. 
Considerable evidence shows that the penetration of the BBB by C. neoformans may 
occur via infected phagocytes (Charlier et al., 2009) or transcellularly through 
adherence and phagocytosis by the brain microvascular endothelial cells (Chang et al., 
2004a; Shi et al., 2010). Determining the relative contribution of these different routes 
to CNS cryptococcosis requires quantitative analysis of the interaction between 
cryptococci and brain microvascular cells, data that are currently lacking.  Here we 
have taken the first steps to address this shortfall by using both mouse and human 
brain endothelial cell models.   
 
Our data indicate that adherence to, and phagocytosis of, cryptococci by brain 
microvascular endothelial cells is a rare event, although one that increases with 
extended periods of incubation.  The rate of encapsulated and acapsular cryptococci 
association with bEnd3 cells remained low even with IFN-γ induction. IFN-γ treated 
and non-treated bEnd3 cells equally associated with cryptococci, an indication that the 
association of cryptococci with bEnd3 cells may be independent of IFN-γ induced 
expression cell adhesion molecules. These findings support recent observations in a 
mouse cryptococcosis model, which suggest that transmission across the BBB is a 
non-specific event dependent on trapping of cryptococci in narrow brain followed by 
phagocytosis after a significant time of contact with brain microvascular endothelial 
cells (Shi et al., 2010). This implies that the adherence to – and phagocytosis of - 
cryptococci by BMEC is a slow process involving single cryptococci binding at any 
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one time and thus that cryptococcal meningoencephalitis may be the result of a very 
small number of cryptococcal cells penetrating the BBB and subsequently 
proliferating to high numbers within the brain tissue (Lee et al., 2010). If so, then 
clinical approaches that reduce cryptococcal binding to endothelia even marginally 
may result in significant improvements to patient health. 
 
Possession of a capsule is a major virulence factor in C. neoformans and the presence 
of a capsule modulates many aspects of the interaction between cryptococci and 
infected hosts (Syme et al., 1999; Zaragoza et al., 2008). Cryptococcus – endothelial 
cell interaction studies have demonstrated varying contribution of the capsule and or it 
absence to cryptococcal binding and uptake by BMEC (Charlier et al., 2005a; Fries et 
al., 2001; Guerrero et al., 2006; Ibrahim et al., 1995; Jain et al., 2006b). By studying 
isogenic pairs of wild type and acapsular cryptococci and different brain endothelial 
cell-lines, we have shown that binding and uptake of cryptococci by BMEC is capsule 
independent.  In agreement with this finding, intravital imaging of cryptococcal 
traversal of the blood-brain barrier has demonstrated equivalent crossing of the blood-
brain barrier by wild type and acapsular cryptococcal yeast cells (Shi et al., 2010), an 
observation that implies the dispensability of the capsule for cryptococcal penetration 
of the blood-brain barrier.  
 
Our finding that neither opsonisation nor active signalling from the cryptococcal cell 
are required for uptake are in line with recent data suggesting that cryptococcal uptake 
into brain endothelia is mediated by binding of endothelial CD44 to hyaluronic acid 
on the yeast surface (Huang et al., 2011). Heat killing of the yeast is unlikely to 
disrupt this interaction, explaining why endothelial invasion by heat-killed 
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cryptococci is seen both in vitro (this study) and in vivo (Shi et al., 2010). 
Interestingly, however, our data suggest that human derived endothelia (but not 
murine bEnd3 cells) are capable of killing intracellular cryptococci.  Presumably 
crossing the BBB intact thus requires one or more of the virulence factors used by 
cryptococci to resist phagosomal killing (Ma et al., 2009), explaining why heat-killed 
cryptococci can enter endothelial cells but are not seen to transmigrate.   
 
5.2 Macrophages and clinical cryptococcosis 
 
In the second part of this thesis we have used an in vitro model of phagocyte – 
Cryptococcus interaction to explore the impact of this interaction on clinical 
parameters and thus on clinical outcome. Our results show that high cryptococcal 
uptake by macrophages is correlated with high cerebral spinal fluid fungal burden. 
The significance of this association is weak (P = 0.035), but given the fact there are 
numerous other factors that together underlie the patient’s clinical outcome, even a 
relatively weak association is likely to indicate an important phenotype for the 
pathogenesis of cryptococcal meningitis. Interestingly, patients with high CSF fungal 
burden are most likely to die by 10 weeks from diagnosis (Bicanic et al., 2009).  Thus 
our data would suggest that high phagocytic uptake is ultimately an indicator of poor 
prognosis for cryptococcal meningitis patients. This counterintuitive correlation may 
have two (non-exclusive) potential explanations. Firstly, high uptake isolates may 
disseminate faster into the brain by using macrophages as vectors. Once in the brain, 
the cryptococci-laden macrophages may either expel or lyse to release cryptococci 
into neuro-cerebral tissue. Unlike low uptake isolates, macrophages exposed to high 
uptake isolates were often observed highly loaded with cryptococci at 2hr of 
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incubation, suggesting that such isolates are likely to generate a high force of 
infection into neural tissue, even in the absence of opsonin.  The macrophage 
intracellular environment provides a protective niche to grow and spread to other cells 
and tissues for which C. neoformans apparently employs the “get in fast” strategy. 
Monocytes from HIV patients are less able to internalize cryptococci (Monari et al., 
1997) so cryptococci that are more rapidly taken up by these macrophages may have 
an advantage in disseminating into the brain. Indeed, studies have shown that that 
cryptococci-laden monocytes (Chretien et al., 2002), and or perivascular macrophages 
(Shinoe et al., 2006) are seen circulating or lodged in the perivascular spaces of in the 
brain capillaries respectively. Secondly, intracellular cryptococci are more slowly 
cleared by antifungal treatment, since most antifungals show poor cellular penetration.  
Thus high uptake strains may disseminate more rapidly to other tissues by ‘hijacking’ 
host phagocytes and are additionally protected from the worst effects of therapy 
during their journey to the brain. 
 
The nature of the host cytokine response is important in determining the fate of 
cryptococcal infection as well influencing clinical outcome. For instance, the presence 
of IFN-γ in the CSF improves both rates of fungal clearance and clinical outcome  
(Bicanic et al., 2009a). We tested the association of cryptococcal uptake, IPR and 
patient CSF cytokine (IFN-γ, IL-6 and TNF-α) levels. These analyses revealed 
intracellular proliferation rate and CSF TNF-α levels to be negatively correlated, 
implying that the higher the intracellular proliferation rate the lower CSF TNF levels. 
TNF-α is a macrophage produced pro-inflammatory cytokine and has been implicated 
in restricting intracellular proliferation of M. tuberculosis in macrophages as well as 
promoting granuloma formation responsible for containing M. tuberculosis infection 
 144 
(Bean et al., 1999).  Thus the presence of intracellular cryptococci may suppress TNF-
α production by macrophages resulting in lower levels of the cytokine. Interestingly, 
the high IPR isolates were also found to express larger capsules and studies have 
shown that the polysaccharide capsule negatively modulates monocyte/macrophage 
cytokine production by inhibiting pro-inflammatory cytokines and enhancing anti-
inflammatory cytokine production (Reviewed in Vecchiarelli and Monari, 2012). The 
paucity of pro-inflammatory cytokines observed in CM patients (Boulware et al., 
2010), may be partly explained by intracellular cryptococci inhibiting cytokine 
production by macrophages. Kawakami et al demonstrated that cryptococci could 
inhibit TNF-α production by macrophages both in vivo and in vitro (Kawakami et al., 
1996; Kawakami et al., 1997). These observations concur with a study, which 
implicated brain macrophages/microglia as the most reactive cells in CM pathology 
and any deficiency in their effector functions results in accumulation of cryptococci in 
the brain (Lee et al., 1996).  
 
Capsule expression and melanin are crucial virulence factors in the pathogenicity of 
C. neoformans. The capsule is involved in evasion and modulation of the immune 
response whereas melanin functions as an antioxidant, protecting the fungus from 
reactive oxygen species generated by phagocytes (Garcia-Rodas and Zaragoza, 2012; 
Jacobson and Tinnell, 1993; Vecchiarelli and Monari, 2012). We characterized all the 
isolates used in Chapter IV for capsule expression and rate of melanin production. 
Our results show that the capsule diameter is inversely correlated with high 
cryptococci uptake by macrophages. This suggests that hypocapsulated isolates are 
more successfully engulfed by macrophages than the hypercapsulated ones, 
confirming the role of the capsule in resisting phagocytosis. The results are in 
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agreement with earlier phagocytosis studies, which showed that cryptococci 
phagocytosis by alveolar macrophages was inversely related to capsule size (Bolanos 
and Mitchell, 1989b) and further demonstrated that large encapsulated strains were 
not taken up in absence of serum (Bolanos and Mitchell, 1989a). While resisting 
phagocytosis is a strategy deployed by some strains of C. neoformans to evade the 
fungicidal effects of the immune response, hypocapsulation most likely offers an 
alternative means of evading the immune response by hiding inside phagocytes such 
as macrophages and monocytes. Studies have shown the cryptococcal capsule 
enlarges during infection and intracellular survival (Zaragoza et al., 2008) but there 
seems to be a population of evolutionarily hypocapsulated strains existing in the 
environment with an ability to infect and cause disease in the human host without 
altering their capsule size. Such hypocapsulated strains were first reported in the 
Lancet, 1985 as a cause of cryptococcal meningitis (CM) in AIDS patients (Bottone et 
al., 1985). Bottone, further argues that the impaired immune response immune in 
AIDS imposes less selective pressure on C. neoformans and hence, the retention of 
poorly encapsulated cells (Bottone et al., 1986). These observations were further 
supported by a study in which a capsule-deficient isolate from the brain of a CM 
patient did not form capsule for 2 weeks in the inoculated murine peritoneal cavity. 
The same study showed this capsule-deficient isolate was highly phagocytosed by 
phagocytes in vitro (Sugiura et al., 2005). Patient CSF cultures were always negative, 
suggesting that the isolate’s susceptibility to phagocytosis prevented detection by 
growth culture since it may have been hidden inside phagocytes (Sugiura et al., 2005). 
Unlike capsule expression, rate of melanisation was positively correlated with 
cryptococcal uptake into macrophages, an indication that the high uptake isolates are 
fast melanin formers.  The rate of melanin formation was significantly increased (P = 
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0.0002) when isolates were passaged in macrophages, suggesting that the intracellular 
environment has an impact on the expression of melanin forming genes.  This is most 
likely an evolved trait, selected for by environmental phagocytes such as amoebae; 
strains that are inherently ‘easily eaten’ must have alternative means, such as 
melanisation, for surviving within soil predators. Interestingly, the high uptake, fast 
melanin forming and high fungal burden isolates were less encapsulated, suggesting 
that C. neoformans employs multiple and varied virulence strategies to adapt to and 
colonize host tissues - in this case, with capsule deficiency being compensated for by 
high melanin formation. 
 
The mechanism to explain why highly phagocytosed isolates are responsible for high 
CSF fungal burden remains unclear. It could be that, in addition to trafficking more 
successfully to the CSF, such strains grow more rapidly under limited nutrient supply 
or they are better survivors. To this end, we tested the high uptake and low uptake 
isolates’ ability to grow on limited iron supply and specific sources of iron. Our 
results show that both sets of isolates are sensitive to low iron conditions, although the 
high uptake isolates grew slightly better in these conditions. In contrast, the laboratory 
reference strain H99 grew extremely well on low iron, a remarkable trait that sets it 
apart from other recently isolated clinical strains of the same species and serotype. 
H99 was isolated in 1978 from the CSF of a Hodgkin’s disease patient (Morrow et al., 
2012) and is currently the reference genome for serotype A C. neoformans.   
 
High uptake strains showed a preference for growth on transferrin as a source of iron 
while the low uptake isolates grew better on heme. Transferrin is widely available in 
human brain tissue with the choroid plexus being the main producer of brain 
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transferrin (Dwork et al., 1988). Therefore an ability to efficiently utilize transferrin 
as a source of iron might explain why high uptake isolates are responsible for high 
fungal burden possibly due to high growth rates in CSF. C. neoformans take up iron 
from transferrin using the high affinity permease/ferroxidase system and mutants in 
this uptake mechanism were unable to grow on transferrin as a source of iron and 
exhibited less virulence with poor dissemination to the brain in a murine model of 
cryptococcosis (Jung et al., 2009). It is important to note that there were within-group 
variations for iron source utilization capabilities with CCTP3, CCTP10 and CCTP13 
of the high uptake group being outstanding for transferrin use while RCT7, RCT33 
and IFN16 in the low uptake group being outstanding for heme utilization. These 
isolates are good candidates for studying the transferrin and heme utilization 
mechanisms. 
 
Last but not the least we tested the isolates for their survival in whole blood from 
healthy donors. Both high and low uptake cryptococci exhibited relatively 
unhampered survival in whole blood, although the high uptake isolates showed 
significant (P = 0.01) resistance to killing by blood in the first 30 min of incubation 
compared to the low uptake isolates.  We thus hypothesized that high uptake isolates 
associate quickly with blood phagocytes, particularly monocytes, which offer them 
protection from fungicidal proteins like complement. A flow cytometry analysis of 
cryptococci-phagocyte association showed a generally equal rate of association with 
monocytes and neutrophils by both high uptake and low uptake isolates. Interestingly, 
however, low uptake isolates seemed to associate better with both monocytes and 
neutrophils than did high uptake isolates (Figure 30 and 30). These observations 
suggest that the cryptococci-blood phagocyte association mechanism may be different 
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from that of tissue macrophages. The distinction between the easily and poorly 
phagocytosed cryptococci is most likely very important within the lungs, when C. 
neoformans first encounters alveolar macrophages. This encounter may subsequently 
define rates of dissemination with the high uptake isolates disseminating faster to the 
brain, suggesting that the rate of brain involvement may largely depend on the rate of 
pulmonary phagocytosis of cryptococci. This hypothesis could be tested in the murine 
inhalation model to confirm the dissemination rates and brain fungal burden in mice 
infected with high uptake and low uptake isolates. 
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6.0 Conclusion 
 
Cryptococcal infection of the brain is the end result of a journey through hurdles 
imposed by the host. Entering the highly protected environment of the brain requires 
cryptococci to overcome barriers in the lung, circulatory system and, most 
significantly, the blood-brain barrier. Alveolar macrophages are key in the pulmonary 
response to cryptococci and the ability of cryptococci to survive and replicate inside 
these macrophages creates a path for transmission from the lung to systemic 
circulation. Cryptococci are endowed with protective strategies such as the production 
of capsule and melanin to downplay the antimicrobial activity of phagocytic cells 
such as monocytes and neutrophils as well as of complement proteins. At the brain 
gate, the blood-brain barrier, cryptococci can gain entry hidden inside phagocytes, by 
being engulfed directly by the brain microvascular endothelial cells or by inducing 
damage to tight junctions to pave the way between brain endothelial cells. Once in the 
brain, the fungus proliferates, resulting in devastating inflammation of the meninges 
and brain parenchyma (meningoencaphalitis). The fact that the probability of survival 
from cryptococcal meningoencephalitis is less than a half, even with treatment, makes 
improved diagnostic and therapeutic developments, as well as interventions focusing 
on the pulmonary and pre-brain systemic life of C. neoformans, critical in order to 
reduce mortality from this disease.  
6.1 Future perspectives 
 
Our current understanding of the underlying mechanisms in the pathogenesis of 
cryptococcosis largely stem from animal models of infection. Indeed through 
mammalian/non-mammalian and tissue culture models, various aspects of 
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cryptococcosis including pathogen virulence, manipulation of host immune response 
and penetration of blood brain barrier have been illustrated (Sabiiti et al., 2012). The 
challenge, however, is to what extent observations made in these models can explain 
what happens in the human host. For every infection, colonization, disease 
progression and clinical outcome are mutually modulated by interplay between 
pathogen and host factors, which makes it challenging to decipher the human host 
factors by studying the pathogen in a different host. Fortunately, over the past decade 
there has been an appreciable increase in clinical research on cryptococcosis and thus 
we envision that future research will see more clinical analysis, which will bridge the 
gap between laboratory models of infection and patient clinical parameters. Direct 
clinical analysis of samples and general underlying physiological parameters of 
patients will provide reference for observations made in laboratory models of 
infection. 
 
Del Poeta and Casadevall have recently contextualized a series of major unanswered 
questions in cryptococcosis (Del Poeta and Casadevall, 2012), ranging from the 
nature of the infectious propagule to the possibility of predicting the likelihood of 
haematogenous dissemination to the brain.  In addition, there remain critical 
unanswered questions about the behaviour of cryptococci in the environment.  For 
instance, what are the nutritional requirements for cryptococcal growth in soil, pigeon 
excreta or on trees (Casadevall and Perfect, 1998; Chowdhary et al., 2012; Sorrell et 
al., 1996), and what is the nature of the relationship between plants and 
Cryptococcus? For instance Waikedere et al have shown that essential oils extracted 
from two species of Heartwood tree, Callitris neocaledonica and C. sulcata can 
inhibit growth of various human fungal pathogens including C. neoformans 
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(Waikedre et al., 2012). Thus research into understanding C. neoformans in its natural 
environment will be crucial in developing better control measures as well as 
identifying new anti-cryptococcal compounds. 
 
In addition, understanding the molecular basis of the host-pathogen interaction will be 
crucial for effective management of cryptococcal disease as well as discovering novel 
therapeutic targets. Despite having relatively similar level of exposure to potentially 
Cryptococcus infested environments, not all immunosuppressed people develop 
cryptococcosis (Del Poeta and Casadevall, 2012). Identifying host (genetic) factors 
that underlie differences in susceptibility to cryptococcal infection is thus a major 
priority. Equally important will be pathogen transcriptomics and proteomics, 
especially of clinical isolates, to uncover virulence factors responsible for disease in 
different groups of patients.  
 
The damage caused by cryptococcal meningoencaphalitis is in most cases irreparable 
with mortality reaching 100% in some cohorts even with antifungal treatment  
(Mwaba P. et al. , 2001). While rabbits have to be therapeutically immunosuppressed 
by repeated treatment with steroids for meningoencephalitis to take effect (Lee et al., 
2010; Perfect et al., 1980; Rude et al., 2002), the effects of cryptococci in the human 
brain are equally devastating to both the immunodeficient and immunocompetent 
patients (Lee et al., 2011).  To this end, the ultimate prize for the future will be to 
prevent, rather than cure, cryptococcal infections. 
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APPENDIX 
Appendix 1: Melanisation scores  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 MR
CM20 0.5 1.5 2.3 3 3.5 3.75 3.8 4 4.5 4.8 5 5 5 5 5 0.56
CM24 0.5 2 3.5 4 4.5 4.75 5 5 5 5 5 5 5 5 5 1.15
CM36 0.8 2.5 3.3 3.3 3.25 3.5 4.5 4.5 5 5 5 5 5 5 5 0.67
CM50 0.8 2.5 3 3 3.5 3.75 3.8 4.25 4.8 5 5 5 5 5 5 0.595
CM52 0.5 1.5 2.8 3.8 4.25 4.5 4.8 4.75 5 5 5 5 5 5 5 0.86
CM64 0.8 1.8 3.8 4 4.25 4.5 4.8 5 5 5 5 5 5 5 5 0.86
CCTP2 0 0.3 1.3 2.2 3.3 4 4.5 4.8 5 5 5 5 5 5 5 0.71
CCTP3 0 1.8 3 4 4.5 4.8 4.8 5 5 5 5 5 5 5 5 1
CCTP10 0 0.8 2 3.1 4.3 4.6 4.8 5 5 5 5 5 5 5 5 0.83
CCTP12 0 0.2 1.3 2 2.7 4 4.5 4.8 5 5 5 5 5 5 5 0.71
CCTP13 0 0.8 1.8 3.2 4 4.5 4.6 5 5 5 5 5 5 5 5 0.83
CCTP25 0 0 0.2 0.5 1.3 2.2 2.5 3.2 3.3 3.8 4.3 4.5 4.5 4.5 4.8 0.42
CCTP26 0 0.3 0.6 1.4 2.1 3 3.6 3.9 4.3 4.5 4.9 5 5 5 5 0.5
CCTP29 0 0.3 0.7 2.3 3.5 3.8 4.7 5 5 5 5 5 5 5 5 0.42
CCTP30 1.5 2.9 3.6 4.3 4.8 4.9 5 5 5 5 5 5 5 5 5 1
CCTP49 0.5 1.3 2.5 2.8 3.5 4 4 4 4.3 4.3 4.5 4.5 4.5 4.8 5 0.48
CCTP52 0.5 1.8 2.3 3 3.25 3.5 3.8 4 4 4.3 4.5 4.5 4.5 5 5 0.48
IFN1 0 0.2 0.3 0.8 1.7 2.3 2.8 3.3 3.8 3.8 4 4.3 4.3 4.3 4.8 0.33
IFN2 0.2 0.5 0.8 1.5 2.2 2.5 2.8 3.8 4.2 4.7 5 5 5 5 5 0.5
IFN4 0.5 2.5 3.5 3.6 4.3 4.5 4.8 4.8 4.8 5 5 5 5 5 5 0.83
IFN5 0 0.2 0.5 0.7 0.8 1.2 2 2.3 3.3 3.5 4.2 4.3 4.7 4.8 4.8 0.42
IFN6 0 0 0.3 1.3 2 2.7 3.7 3.7 3.7 3.8 4.2 4.5 4.5 4.7 4.8 0.71
IFN8 0.2 1.8 3.3 3.5 4.2 4.3 4.7 4.8 4.8 5 5 5 5 5 5 0.71
IFN9 0 0.3 2 2.5 3.2 3.6 4.1 4.2 4.3 4.3 4.7 4.8 4.8 5 5 0.46
IFN10 0 0.3 0.8 1.8 3.1 3.7 4 4.7 4.7 4.7 4.8 5 5 5 5 0.63
IFN11 0 0.2 1 1.5 2.7 3.7 4.5 4.8 5 5 5 5 5 5 5 0.71
IFN12 0 0.2 0.5 1.2 1.5 1.8 2.2 2.7 3.3 3.7 3.8 4.2 4.3 4.3 4.7 0.5
IFN15 0 1 1.7 2.3 3 3.7 4.2 4.7 4.8 5 5 5 5 5 5 0.63
IFN16 0.2 0.5 1.2 1.7 2.3 2.3 2.7 2.8 3.5 3.7 4 4.3 4.7 4.7 4.7 0.39
IFN17 0.2 1.3 2.7 3.3 3.8 4.2 4.2 4.5 4.7 5 5 5 5 5 5 0.63
IFN18 0 0.7 1.7 2.7 3.5 3.8 4 4.5 4.7 4.7 5 5 5 5 5 0.63
IFN19 0 0.2 0.7 1.3 1.7 2.2 2.7 3.8 3.8 4 4.5 5 5 5 5 0.455
IFN24 0.2 0.2 2.3 3.3 4 4.8 5 5 5 5 5 5 5 5 5 0.83
RCT3 0 0.5 1.5 2.7 3.2 4 4.3 4.7 4.7 5 5 5 5 5 5 0.63
RCT6 0.5 1.8 2.8 3 3.5 3.75 4.3 4.5 4.8 5 5 5 5 5 5 0.63
RCT7 0 0.3 1.2 1.5 2.3 3 3.2 3.5 4 4 4.2 4.7 4.8 4.8 5 0.42
RCT21 0.5 1.5 3.3 4 4 4.5 4.5 4.5 5 5 5 5 5 5 5 0.83
RCT24 0 0.2 0.7 1.8 3.3 4.3 4.7 4.8 5 5 5 5 5 5 5 0.71
RCT33 0 0.3 1 1.3 2.2 2.7 3.2 3.5 3.67 3.8 4.2 4.7 4.8 5 5 0.39
RCT36 0 1 2 2.7 3.5 4 4.3 4.8 4.8 5 5 5 5 5 5 0.63
RCT44 0.2 1.8 3.5 4.7 4.8 5 5 5 5 5 5 5 5 5 5 1.3
RCT50 0 0.3 1.7 2 2.3 3.2 3.7 3.8 4.3 4.7 4.8 4.8 4.4 5 5 0.5
RCT51 0 0 0.7 1.3 2.1 3.2 3.5 4 4.2 4.7 4.7 4.8 4.8 4.8 5 0.5
RCT52 0 0.5 1.3 1.7 2.7 3.3 3.8 4.2 4.3 4.7 5 5 5 5 5 0.5
RCT54 0.5 1.8 3.5 3.8 4 4.5 4.5 4.75 5 5 5 5 5 5 5 0.83
RCT55 0 0.5 1.5 2 2.7 3 3 3.7 4 4.3 4.7 4.7 4.8 5 5 0.46
RCT60 0.2 1.2 1.8 2.3 2.8 3.5 3.7 4 4.5 4.8 4.8 4.8 4.8 5 5 0.55
H99 0.2 3.5 4.7 5 5 5 5 5 5 5 5 5 5 5 5 1.67
B3501 0 0 0.17 0.5 1.33 2.17 3.33 4.33 4.83 5 5 5 5 5 5 0.53
Daily melanization score (Mean) 
Isolate
The red and blue coloured numbers are melanisation rates of H99 (laboratory 
reference strain) and RCT44 (highest MR in the set of clinical isolates) respectively. 
Like in the low iron medium growth phenotype, strain H99 again shows remarkably 
higher rate of melanisation than the clinical isolates.  Scores are mean of 3 repeats for 
CCTP and RCT isolates and 2 repeats of CM isolates.  
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Appendix 2: The bioanalysis results of RNA extracts before RNA sequencing 
   
Appendix 2A: Graphs showing the 18s and 28s picks of RNA samples determined by the Bioanalyzer. The first pick on the left side in all graphs 
represents the ladder. 2CM36 = CM36, 1CM50 = CM50. 
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Library 
name 
Sample 
name Library type 
Volume 
(µL) 
Conc. 
(ng/µL) 
Size 
(bp) RIN Result 
1 CCTP13 CCTP13 RNA library 60 49 452 9.7 Pass 
2 CCTP3 CCTP3 RNA library 60 56 454 9.8 Pass 
3 CCTP10 CCTP10 RNA library 60 62 464 9.6 Pass 
4 CCTP30 CCTP30 RNA library 30 101 ND 9.6 Pass 
5 RCT60 RCT60 RNA library 60 62 415 8.4 Pass 
6 IFN16 IFN16 RNA library 60 56 423 9.5 Pass 
7 CM36 CM36 RNA library 60 98 450 9.8 Pass 
8 CM50 CM50 RNA library 60 43 425 9.4 Pass 
9 H99 H99 RNA library 60 44 464 9.5 Pass 
 
Appendix 2B: The quantity and RNA integrity (RIN) of the RNA samples. 
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Appendix 3: Growth rates in low iron and rich media 
 
 
 
Growth rate on different media 
Isolate Lim Transferrin Heme YPD 
CCTP2 -0.0066 0.2612 0.0958 0.7154 
CCTP3 0.2064 0.43335 -0.1353 0.6775 
CCTP10 -0.0211 0.6096 -0.1476 0.6894 
CCTP13 0.0213 0.5707 0.06 0.7247 
CCTP30 0.03857 0.0961 -0.0213 0.3324 
H99 0.5643 0.5351 0.6861 0.3499 
RCT7 0.1589 0.3776 0.1935 0.4124 
RCT33 0.1646 0.2014 -0.02003 0.6144 
RCT60 -0.224 -0.2311 -0.0374 0.1772 
IFN16 0.3041 0.2427 0.30275 0.3935 
CM36 -0.1355 -0.0405 0.0082 0.1636 
CM50 -0.17 -0.2125 0.3035 0.3804 
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Appendix 4: Non-grouped plot of percentage association of 
cryptococci with monocytes in whole blood 
 
 
Fresh whole blood from healthy donors was incubated with FITC stained cryptococci 
(104 cells per 1ml of whole blood) for 60min. By flow cytometry the cryptococci 
associated with monocytes were determined using forward and side scatter. Unlike 
macrophages, there was generally no difference between high (blue bars) and low 
(black bars) uptake isolates’ association with monocytes in whole blood. Error bars 
are standard error of the mean (n = 4 donors). 
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Appendix 5: Non-grouped plot of percentage association of 
cryptococci with neutrophils in whole blood 
 
 
Fresh whole blood from five healthy donors was incubated with FITC stained 
cryptococci (104 cells per 1ml of whole blood) for 60min. By flow cytometry the 
cryptococci associated with monocytes were determined using forward and side 
scatter. As with monocytes, there was generally no difference between high (blue 
bars) and low (black bars) isolates’ association with neutrophils in whole blood. Error 
bars are standard error of the mean (n = 5 donors).  
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Appendix 6: Gene expression comparison between clinical isolates and reference strain H99 
 
Compariso
n
Statistical 
method
Informative 
genes
Significant 
genes UP_all UP_2-4 UP_ gte4 Down_all Down_ 2-4 Down_ gte
Low$vs$High QuasiSeq 6846 8 3 1 2 5 2 3
CCTP10$vs$
H99
Fisher's$
exact$test 6838 933 178 136 42 755 574 181
CCTP13$vs$
H99
Fisher's$
exact$test 6834 1249 1124 977 147 125 69 56
CCTP3$vs$
H99
Fisher's$
exact$test 6849 776 482 349 133 294 240 54
CCTP30$vs$
H99
Fisher's$
exact$test 6849 1343 347 269 78 996 790 206
CM50$vs$H99 Fisher's$exact$test 6837 1421 194 151 43 1227 976 251
CM36$vs$H99 Fisher's$exact$test 6834 1353 319 270 49 1034 760 274
IFN16$vs$H99 Fisher's$exact$test 6844 2311 1085 880 205 1226 926 300
RCT60$vs$
H99
Fisher's$
exact$test 6845 1602 572 448 124 1030 860 170  
!
The overall differentially expressed genes between the Low and High uptake isolates (green row).  High uptake (Orange highlighted rows) and 
low uptake (Yellow rows) isolates pairwise comparisons with H99 respectively.  UP_all = the number of genes exhibiting upregulated profile in 
high uptake isolates, UP_2-4 = number genes exhibiting 2-4 fold upregulated profile in high uptake group relative to low uptake group, UP_gte4 
= number genes exhibiting 4 fold upregulated profile high uptake group relative to low uptake group, DOWN_all = number genes exhibiting 
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downregulated profile high uptake group relative to low uptake group, DOWN_2-4 = number genes exhibiting 2-4 fold down regulated profile in 
high uptake isolates relative to low uptake group,  and DOWN_gte4 = number genes exhibiting 4 fold down regulated profile in high uptake 
isolates relative to low uptake group.
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Appendix 7: List of isolate charcteristics grouped by median 
uptake by macrophages 
 
 
The table represents all the 47 isolates with determined phenotypes (Uptake, IPR, 
melanisation rate, Mel. Rate, capsule diameter (Cap. Diam) divided into two groups 
by the Median (420) of uptake. Upper division is (yellow) is uptake below 420 
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cryptococci/µl lysate whilst the lower division (orange) are those whose rate of uptake 
is higher than 420 cryptococci/µl lysate. Interestingly the three highest uptake 
(CCTP3, CCTP30 and CCTP13) isolates belong to same MLST 5 while the two 
lowest uptake isolates (CM36 and CM50) are both MLST 6.  
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Abstract
Cryptococcosis is a life-threatening fungal disease with a high rate of mortality among HIV/AIDS patients across the world.
The ability to penetrate the blood-brain barrier (BBB) is central to the pathogenesis of cryptococcosis, but the way in which
this occurs remains unclear. Here we use both mouse and human brain derived endothelial cells (bEnd3 and hCMEC/D3) to
accurately quantify fungal uptake and survival within brain endothelial cells. Our data indicate that the adherence and
internalisation of cryptococci by brain microvascular endothelial cells is an infrequent event involving small numbers of
cryptococcal yeast cells. Interestingly, this process requires neither active signalling from the fungus nor the presence of the
fungal capsule. Thus entry into brain microvascular endothelial cells is most likely a passive event that occurs following
‘trapping’ within capillary beds of the BBB.
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Introduction
Cryptococcosis is a life-threatening disease caused primarily by
the human fungal pathogen Cryptococcus neoformans. Cryptococcal
infection can potentially occur in any part of the human body
(reviewed in [1]), although central nervous system (CNS)
cryptococcosis accounts for most clinical presentation. Globally,
fatalities due to cryptococcal meningitis were recently estimated at
over 600,000 cases per year of which 504000 (81%) occur in Sub-
Saharan Africa [2]. The victims of cryptococcal infection are
predominantly immunocompromised people infected with C.
neoformans, although there is an increasing incidence of immuno-
competent cryptococcosis caused by C. gattii [3–7]. HIV/AIDS is
the major predisposing condition for cryptococcosis with 10–15%
HIV patients acquiring cryptococcal infection, although prolonged
glucocorticosteroid therapy and solid organ transplantation are
increasingly becoming important [8,9].
The route of cryptococcal infection is believed to be through
inhalation of airborne basidiospores or desiccated yeast cells from
an environmental source to the lungs. The fungal yeast cells may
stay dormant in the host, and can potentially disseminate to all
body organs but there is a high propensity of dissemination to the
brain [10]. Once in the brain the fungus causes meningoenceph-
alitis, a severe form of the disease, which is uniformly fatal if
untreated [11]. Even with the most effective antifungal therapy,
the fatality rate remains high in HIV-associated crytococcosis (10–
25% and .40% in rich and poor settings respectively [12–17]
Dissemination to the brain requires that C. neoformans penetrate the
normally impermeable blood-brain barrier (BBB) [18]. The BBB is
made of microvascular endothelial cells supported by astrocytic
foot processes, pericytes and neuronal processes [19]. Brain
microvascular endothelial cells form strong tight junctions, which
present a formidable barrier to any invading pathogens [18–20].
The mechanism by which C. neoformans penetrates this barrier is
not currently understood, although several possibilities have been
proposed, including passage between neighbouring endothelial
cells (paracellular entry), carriage into the CNS within infected
phagocytes (Trojan Horse model), or uptake by and traversal
through endothelial cells (transcytosis) [21,22]. In the transcellular
model of traversal, adherence to and uptake of cryptococci by
brain microvascular endothelial cells (BMEC) must occur before
transit into the brain. In support of this model, Chang et al used
electron microscopy to demonstrate that cryptococcal yeast cells
could adhere to and become internalised by brain microvascular
endothelial cells [23].
Several pathogen-generated microbial factors including urease,
laccase, capsule and hyaluronic acid have been implicated in
modulating the Cryptococcus – blood-brain barrier interaction
[24,25]. The capsule is a major virulence factor and its role in
pathogen – phagocyte interaction and systemic dissemination of
Cryptococcus is well documented [26]. However, the role of capsule
in regulating CNS invasion remains unclear. Capsule associated
structural changes such as phenotypic switching (rough to smooth)
have been reported to enhance crossing of the blood-brain barrier
[27–31], but a recent study using intravital real time imaging
demonstrated that encapsulated and acapsular strains of C.
neoformans had an equal ability to associate with – and transmigrate
across - the microvascular endothelium into the brain [32].
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Despite these recent advances, however, there are currently no
quantitative data on cryptococcal uptake by brain endothelial cells
in the presence and absence of capsule. Here we report the first
attempts to address this, by using an in vitro brain endothelial cell
culture to quantify association and uptake of cryptococci.
Materials and Methods
Yeast culture
Two sets of isogenic C. neoformans strains, serotype A H99 and its
isogenic acapsular strain cap59 and serotype D B3501 with its
isogenic acapsular strain B4131 were used. Strains were
propagated on YPD agar (1% yeast extract, 1% peptone, 2%
dextrose and 1% agar) at 25uC. Prior to experimentation, cultures
of both strains were grown in YPD broth (1% yeast extract, 1%
peptone and 2% dextrose) at 25uC with rotation at 20 RPM
overnight. The yeast cells were washed with sterile phosphate
buffered saline (PBS) and stained with 0.5 mg/ml FITC for
30 min with shaking (Labrolller, Labnet Inc.) at room tempera-
ture. The required infection inoculum (of 26106 yeast cells) was
determined by counting using a haemocytometer.
Tissue culture
Two types of brain microvascular endothelial cell-lines, the
immortalized mouse brain derived endothelial (bEnd3) cells and
the human brain capillary microvascular endothelial cells
(hCMEC/D3) were used. The bEnd3 cells were grown to
monolayer confluence in 24 well tissue culture plates (Greiner,
UK) containing Dulbecco’s modified Eagle’s medium (DMEM,
Sigma Aldrich) supplemented with 10% foetal bovine serum (FBS),
I% streptomycin/penicillin and 2 mM L-glutamine, 1% non-
essential aminoacids, 1% Sodium pyruvate and 5 mM 2-Mercap-
toethanol. HCMEC/D3 cells were grown in endothelial growth
medium 2 (EGM-2, Lonza, UK) in 24 well tissue culture plates
precoated with Calf Skin collagen (Sigma UK). Seeding plates with
105 endothelial cells per well, ensured even growth of a cell
monolayer. The culture was maintained at 37uC with 5%CO2 for
4–6 days to obtain a fully matured cell monolayer. For
microscopic examination, 13 mm sterile glass coverslips (collagen
coated for hCMEC/D3 cells) were inserted into the 24 well plates
before seeding with endothelial cells, allowing the monolayer to
grow on the coverslip, which could then be easily transferred for
microscopy. Prior to infection, tissue culture growth medium was
replaced with serum free medium and incubated for 1 hr at 37uC.
The cultures were then inoculated with 26106 yeast cells per well,
producing an approximate infection ratio of 1: 3 (target: effector).
Infections were allowed to proceed for either 2 hr or 4 hrs, as
described, at 37uC with 5% CO2. To ensure that the infection
media did not have a negative effect on cryptococcal growth,
cryptococci (105 yeast cells/ml) were directly inoculated into
bEnd3 and or hCMEC/D3 infection medium and growth
recorded over 24 hrs.
Quantification of yeast cell association with, and
internalization by, BMEC cells
The rate of cryptococcal yeast cell association with brain
microvascular endothelial cells (BMEC), bEnd3 and hCMEC/D3
was determined both microscopically and using CFU counts. In
the former, dual colour fluorescence microscopy (Nikon Eclipse Ti
- S, Japan) was used to determine associated (adherent and
internalized) yeast cells. After infection, the non-adherent yeast
cells were removed by washing four times with sterile PBS and the
extracellular adherent yeast cells stained for 10–15 min with
20 mg/ml calcoflour white (adapted from [33]) at room temper-
ature. Since mammalian cells are impermeable to calcofluor white,
internalized yeast retained the green FITC signal while adherent
cells stained blue. Nine random fields per coverslip were viewed
and the internalized and non-internalized yeasts therein counted.
Association (total number of yeast cells –attached or internalized
by BMEC) and internalization were determined and compared to
the original inoculum.
Since this microscopic approach did not distinguish between
live and dead cryptococci, we exploited colony forming unit (CFU)
assays to determine the viability of cryptococci that had been
internalised by cells of the BBB. After removal of non-adherent
cryptococci by extensive washing, endothelial cells were lysed with
200 ml sterile water for 15 min at 37uC to release internalized
cryptococci and the lysate plated on YPD agar for colony counts
(CFU assay). The associated cryptococci were determined as the
ratio of cryptococcal yeast cells (CFU/ml) to the original
inoculum.
Thus, by comparing data derived both from microscopy (which
distinguishes internalised from attached cryptococci, but not live
from dead cells) and from CFU counts (which have the opposite
profile) we were able to accurately estimate both uptake and
survival of cryptococci. The results were recorded as endothelial
cell associated cryptococci per well, which is equivalent to
cryptococci per coverslip for microscopy and CFU/ml for colony
counts.
Opsonisation
Antibodies to Cryptococcus have been reported to exist in
circulation as early as childhood [34]. Furthermore, phagocytosis
studies using macrophages have shown that internalization of
cryptococcal yeast cells is enhanced by antibody and or
complement mediated opsonisation [35–37]. However, no studies
have investigated whether adherence and uptake of cryptococci by
BMEC requires opsonisation. To address this, opsonised and non-
oposonized live and heat killed H99 cryptococci were incubated
with BMEC for 2 hr and 4 hr at 37uC. Opsonisation was done by
adding 5 mg/ml the capsule specific 18B7 mouse IgG (a kind gift
from Arturo Casadevall) to 200 ml aliquot of yeast cells and rotated
(Labroller, Labnet Inc, US) at room temperature for 30 min prior
to infection. The rate of association and internalization was
determined as described above.
Role of viability in Cryptococcus – BMEC association and
internalization
We tested whether dead cryptococci adhere and are internal-
ized by BMEC at the same rate as live cells. 1 ml aliquots of both
encapsulated and non-capsulated cryptococci were heated at 65uC
for 15 min prior to infection. Adherent and internalized yeasts
were determined microscopically. To determine if the yeast
culture was completely killed, 20 ml aliquots were plated on YPD
agar and no growth was observed.
Fixed endothelial cell control
As a negative control, mature endothelial cell (bEnd3 and
hCMEC/D3) monolayers were fixed with 250 ml PFA 4% in PBS
for 10 min at room temperature, rinsed five times with PBS and
then inoculated with 26106 cryptococci per ml. As for the live
endothelial cell monolayers, the fixed monolayers were incubated
with cryptococci for 2 hr and 4 hr at 37uC with 5% CO2 and
washed four times to remove non-adherent yeast cells. 200 ml
sterile water was used to lyse the endothelial cells with additional
scraping to remove any remaining endothelial cell associated
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cryptococci. The lysate was plated on YPD agar at 25uC and
colony counts were made after 48 hr.
Statistical analysis
Non-parametric Mann-Whitney U Test and Wilcoxon Signed
Ranks Test were used to measure the significance of adherence at
different conditions and time points. Mann-Whitney U Test was
applied to compare the means of test different setups, for instance
comparing the mean association of encapsulated and acapsular
strain to bEnd3 and or hCMEC/D3 cells. Wilcoxon Signed ranks
test was applied to compare means of the same setup at different
time points, for example comparing the mean association of
encapsulated H99 strain or the acapsular mutant with endothelial
cells after 2 hrs and 4 hrs of incubation at 37uC.
Results
Cryptococcal association with and internalization by the
murine brain endothelial cell line bEnd3
We exposed the mouse brain endothelial cell line bEnd3 to
wildtype C. neoformans H99 and its isogenic acapsular derivative,
cap59 [38]. The two strains were tested for their rate of binding
and internalization by BMEC and whether the presence or
absence of capsule has an effect on this interaction. After two
hours of exposure to bEnd3 cells at 37uC, 8.86103 (0.43%) of
inoculated wild type (H99) cryptococci had adhered strongly to the
endothelial layer, rising to 2.06104 (1.2%) after four hours.
Similarly, 1.66104 (0.8%) of the acapsular cryptococci had
associated with bEnd3 cells at 2 hr rising to 2.56104 (1.23%)
after four hours of incubation at 37uC (Figure 1A). In contrast,
binding to paraformaldehyde-fixed BMEC monolayers was
negligible at all time points tested (Figure S1). By using calcoflour
staining to discriminate surface bound from internalised crypto-
cocci, we determined that 3.16103 (35% of associated) and
4.46103 (28% of associated) wild type and acapsular cryptococci,
respectively, had been internalised by 2 hours at 37uC, rising to
8.16103 (40%) and 8.66103 (35%) respectively by 4 hrs
(Figure 1B). Importantly, for both strains, microscopic yeast cell
counts and live CFU counts gave the same rate of association for
both H99 and cap59, suggesting that there is no significant drop in
cryptococcal viability upon adherence to or uptake by bEnd3 cells.
Effect of opsonisation on Cryptococcus – BMEC
association and internalization
Since most individuals produce circulating antibodies to
cryptococci by late childhood [34], we investigated whether
opsonisation of cryptococci with antibody increases the association
and internalization with brain endothelial cells. However, there
were no significant differences between opsonised and non-
opsonised yeast in either adherence or uptake at either time point
tested (Figure 2A and B), suggesting binding and uptake by brain
endothelial cells is opsonin independent.
Cryptococcal association and internalization by human
brain endothelial cells, hCMEC/D3
To test whether the rates of adherence and uptake that we had
observed in bEnd3 cells were species specific, we repeated our
analyses using the human brain endothelial derived cell-line,
hCMEC/D3. As with bEnd3 cells, both microscopic and CFU
counts showed that encapsulated H99 and its isogenic acapsular
mutant cap59 associated and were engulfed at the same rate,
P =.0.05 at 2 hr and 4 hr of infection respectively (Figure 3A and
B). To determine whether the interaction varies from strain to
strain, we tested a different pair of C. neoformans serotype D strains;
encapsulated B3501 and its isogenic acapsular strain B4131. Like
the H99/cap59 isogenic pair, both B3501 and B4131 strains
associated and were internalized at the same rate with hCMEC/
D3 cells (Figure 4A and B).
However, unlike bEnd3 cells, we observed a significant decrease
over time in cryptococcal CFU counts for both strains.
Microscopic counts revealed that association and internalization
for both strains increases with time of incubation, suggesting a loss
of viability by cryptococci during association with hCMEC/D3
cells (Figure 3A and 4A). One potential explanation for this result
is that hCMEC/D3 cells may generate a more antimicrobial
environment for cryptococci following uptake than that produced
by bEnd3 cells. Thus bEnd3 cells and hCMEC/D3 cells bind and
engulf cryptococci at similar rates, but only hCMEC/D3 cells are
able to significantly reduce cryptococcal viability following uptake.
Viability of cryptococci is not a prerequisite for
association and internalization by BMEC
Lastly, we investigated whether the uptake of cryptococci into
BMEC requires active signals from the pathogen. However, heat-
killed H99 retained the ability to bind and enter both mouse
bEnd3 and human hCMEC/D3 cells at a similar rate to live yeast
(Figure 5A and C). Although viable cryptococci showed higher
association efficiency in bEnd3 cells, there was no significant
difference between internalization of viable and heat-killed
cryptococci in both bEnd3 and hCMEC/D3 cells. (Figure 5B
and D), suggesting that uptake is a passive process that occurs
independently of yeast cell viability.
Discussion
The mechanism by which C. neoformans associates with – and
penetrates - the BBB remains a critical question in understanding
the pathogenesis of CNS cryptococcosis. Considerable evidence
shows that the penetration of the BBB by C. neoformans may occur
via infected phagocytes [21,39] or transcellularly through
adherence and phagocytosis by the brain microvascular endothe-
lial cells [22,32]. Determining the relative contribution of these
different routes to CNS cryptococcosis requires quantitative
analysis of the interaction between cryptococci and brain
microvascular cells, data that are currently lacking. Here we take
the first steps to address this shortfall by using both mouse and
human brain endothelial cell models.
Our data indicate that cryptococcal association with brain
microvascular endothelial cells is a relatively infrequent event,
although one that increases with extended periods of incubation.
In both cell lines, mouse and human, less than 2% of encapsulated
and acapsular cryptococci were strongly bound by 4 hrs of
incubation. However, once bound, the probability of being
internalized is high (typically .40% within four hours). These
findings support recent observations in a mouse cryptococcosis
model, which suggest that transmission across the BBB is a non-
specific event dependent on trapping of cryptococci in narrow
brain capillaries followed by phagocytosis into brain microvascular
endothelial cells [32]. This implies that the adherence to – and
phagocytosis of - cryptococci by BMEC is a slow process involving
single cryptococci binding at any one time. We thus hypothesize
that cryptococcal meningoencephalitis may be the result of a very
small number of cryptococcal cells penetrating the BBB and
subsequently proliferating to high numbers within the brain tissue.
If so, then clinical approaches that reduce cryptococcal binding to
endothelia even marginally may result in significant improvements
to patient health. On the other hand, the low transcellular uptake
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suggests that C. neoformans might engage multiple entry mecha-
nisms into the brain.
Possession of a capsule is a major virulence factor in C.
neoformans and the presence of a capsule modulates many aspects of
the interaction between cryptococci and infected hosts [40,41].
Cryptococcus – endothelial cell interaction studies have yielded
conflicting results regarding how capsule impacts on cryptococcal
binding and uptake by BMEC [27,29–31,42]. By studying isogenic
pairs of wild type and acapsular cryptococci and different brain
endothelial cell-lines, we have shown that binding and uptake of
cryptococci by BMEC is capsule independent. In agreement with
this finding, intravital imaging of cryptococcal traversal of the
Figure 1. Binding and uptake of H99 and cap59 to the murine brain endothelial cell line, bEnd3. BEnd3 cells were exposed to wild type
H99 and its acapsular derivative cap59 for 2 hr and 4 hr at 37uC. (A) The rate of association (bound and internalized cryptococci) was determined
both by microscopy and live CFU counts. The rate of association increased significantly in a time dependent manner, (P,0.01 for both strains).
However, there was no difference in association of encapsulated H99 or acapsular cap59 cells (P = 0.1 and 0.5 at 2 hr and 4 hr respectively). (B)
Internalization of the two strains, H99 and cap59 by bEnd3 cells as determined by fluorescence microscopy. Internalized cryptococci (pre-stained with
FITC) were distinguished from extracellular adherent ones by counter labelling with calcofluor white after infection. Intracellular cryptococci retained
the FITC green signal while extracellular cells acquired the blue signal from calcofluor. The number of phagocytosed cryptococci increased
significantly in a time dependent manner, (P,0.01 for both strains). However, there was no difference in internalization of encapsulated H99 and
acapsular cap59, (P = 0.5 and 0.8 at 2 hr and 4 hr respectively). Error bars are standard error of the mean, n = 5 repeats.
doi:10.1371/journal.pone.0035455.g001
Figure 2. Effect of opsonisation on cryptococcal binding and uptake by bEnd3 cells. Live (LV) and heat-killed (HK) H99 cryptococci were
opsonised with mouse derived anti-capsule IgG antibody, 18B7 and the rate of adherence and internalization was determined by fluorescence
microscopy. (A) Association of opsonised (op) and non-opsonised (Nop) cryptococci with bEnd3 cells. Rate of association of opsonised and non-
opsonised H99LV cryptococci was similar, P = 0.8 and 0.4 at 2 hr and 4 hr respectively. Similarly, there was no difference between opsonised and non-
opsonised heat-killed H99 cryptococci, P = 0.9 and 0.5 at 2 hr and 4 hr respectively. (B) Rate of internalization of opsonised and non-opsonised
cryptococci internalized by bEnd3 cells. The number of internalized H99LV cryptococci was similar, regardless of opsonisation status (P = 0.9 at both
2 hr and 4 hr). Similarly, there was no difference between opsonised and non-opsonised heat-killed H99 cryptococci, P = 0.5 and 0.4 at 2 hr and 4 hr
respectively. Error bars are standard error of the mean, n = 5 repeats.
doi:10.1371/journal.pone.0035455.g002
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blood-brain barrier has demonstrated equivalent crossing of the
blood-brain barrier by wild type and acapsular cryptococcal yeast
cells [32], an observation that implies the dispensability of the
capsule for cryptococcal penetration of the blood-brain barrier.
Our finding that neither opsonisation nor active signalling from
the cryptococcal cell are required for uptake are in line with recent
data suggesting that cryptococcal uptake into brain endothelia is
mediated by binding of endothelial CD44 to hyaluronic acid on
Figure 3. Binding and uptake of H99 and cap59 with human brain endothelial cell line, hCMEC/D3. Like bEnd3 cells, hCMEC/D3 cells
were exposed to the C. neoformans serotype A isogenic strains, wild type H99 and acapsular derivative cap59 for 2 hr and 4 hr at 37uC. Microscopic
(Mic.) and live CFU counts were performed to determine the association and survival of cryptococci. (A) Association efficiency of H99 and cap59
cryptococci with hCMEC/D3 cells. As opposed to microscopic counts, live CFU counts showed a time dependent decrease in the number of
associated cryptococci by 4 hr of incubation, w=P,0.05 and ww=P,0.01 for H99 and cap59 respectively, suggesting a drop in viability of the
hCMEC/D3 associated H99 and cap59 cryptococci. There was no difference in association of encapsulated H99 and acapsular cap59, P = 0.7 and 0.6 at
2 hr and 4 hr respectively. (B) Internalization of encapsulated H99 and acapsular cap59 cryptococci by human brain endothelial cell line, hCMEC/D3
cells. The internalized cryptococci and extracellular adherent were determined as in Figure 1. As with association, the number of phagocytosed
cryptococci increased significantly in a time dependent manner, P = 0.01 and,0.01 for H99 and cap59 respectively. However, there was no difference
in internalization of H99 and acapsular cap59 cryptococci, P = 0.5 and 0.8 at 2 hr and 4 hr respectively. Error bars are standard error of the mean, n = 6
repeats.
doi:10.1371/journal.pone.0035455.g003
Figure 4. Binding and uptake of B3501 and B-4131 with human brain endothelial cell line, hCMEC/D3. HCMEC/D3 cells were exposed to
C. neoformans serotype D wild type B3501 and its isogenic acapsular mutant B4131 for 2 hr and 4 hr at 37uC. Microscopic and live CFU counts were
performed to determine the association and survival of cryptococci. (A) Association efficiency of B3501 and B4131 cryptococci with hCMEC/D3 cells.
Like the H99-cap59 pair, live CFU counts showed a time dependent decrease in the number of associated cryptococci by 4 hr of incubation,
w=P,0.01, ww=P,0.01 for both B3501 and B4131. There was no difference in association by encapsulated B3501 and acapsular B4131, P-
value =.0.05 at 2 hr of incubation. However, B4131 was significantly more associated, P = 0.02 (Microscopy) and ,0.01 (CFU) by 4 hr of incubation.
(B) Internalization of encapsulated B3501 and its acapsular mutant derivative B4131 by hCMEC/D3 cells determined by fluorescence microscopy (Mic).
The number of phagocytosed cryptococci increased significantly in a time dependent manner, P = 0.01 for both strains. However, there was no
difference in internalization of B3501 and B4131, P = 0.5 and 0.2 at 2 hr and 4 hr respectively. Error bars are standard error of the mean, n = 6 repeats.
doi:10.1371/journal.pone.0035455.g004
Cryptococcal Uptake by BMEC
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e35455
the yeast surface [25]. Heat killing of the yeast is unlikely to disrupt
this interaction. Although viable and non-viable (heat-killed) are
equally internalized (this study), the non-viable cryptococci are
unlikely to survive lysosomal degradation and hence may not
transmigrate across the BBB in vivo [32]. Interestingly, however,
our data suggest that human derived endothelia (but not murine
bEnd3 cells) may be capable of killing intracellular cryptococci.
Presumably crossing the BBB intact thus requires one or more of
the virulence factors used by cryptococci to resist phagosomal
killing [43], explaining why heat-killed cryptococci can enter
endothelial cells but are not seen to transmigrate.
Supporting Information
Figure S1 Binding to fixed endothelial cell monolayers
(negative control). To verify that the observed binding
occurred in association with endothelial cells, and not due to
indirect sequestration of yeast cells, bEnd3 and hCMEC/D3
monolayers were killed by paraformaldehyde fixation prior to
cryptococci inoculation. For all conditions, cryptococcal binding
was reduced by between one and two log orders, indicating that
that viable endothelial cells were responsible for the observed
cryptococcal association.
(TIF)
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